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ABSTRACT
Human T Cell Response to Substrate Rigidity for Design of Improved
Expansion Platform
Sarah De Leo
Cells have long been known to sense and respond to mechanical stimuli in their
environment. In the adoptive immune system particularly, cells are highly special-
ized and responsible for detecting and eliminating pathogens from the body. T cell
mechanosensing is a relatively new field that explores how force transmission in cell-
cell interaction elicits both inter- and intra-cell signaling. Owing to recent advances
in genetic manipulation of T cells, it has emerged as new tool in immunotherapy. We
recently demonstrated human T cell activation in response to mechanical rigidity of
surfaces presenting activating antibodies CD3 and CD28. The work in this dissertation
highlights new progress in the basic science of T cell mechanosensing, and the utilization
of this knowledge toward the development of a more specialized expansion platform for
adoptive immunotherapies.
Human T cells are known to trigger more readily on softer PDMS substrates, where
Young’s Modulus is less than 100 kPa as compared to surfaces of 2 MPa. While the
range of effective rigidities has been established, it is important to explore local differ-
ences in substrates that may also contribute to these findings. We have isolated the
rigidity-dependence of cell-cell interactions apart from material properties to optimize
design for a clinical cell expansion platform. Though PDMS is a well understood bio-
material and has found extensive use in cellular engineering, a PA gel substrate model
allows for rigidity to be tuned more closely across this specific range of rigidities and
provides control over ligand density and orientation. These rigidity-based trends will
be instrumental in adapting models of mechanobiology to describe T cell activation via
the immune synapse.
In what is generally accepted as the clinical gold-standard for T cell expansion,
rigid (GPa) antibody-coated polystyrene beads provide an increase in the ratio of stim-
ulating surface area-per-volume, over standard culture dishes. Herein we describe the
development of a soft-material fiber-based system with particular focus on maintaining
mechanical properties of PDMS to exploit rigidity-based expansion trends, investigated
through atomic force microscopy. This system is designed to ease risks associated with
bead-cell separation while preserving a large area-to-volume ratio. Exposing T cells to
electrospun mesh of varying rigidities, fiber diameters, and mesh densities over short (3
day) and long (15 day) time periods have allowed for this system’s optimization.
By capitalizing on the mechanisms by which rigidity mediates cell activation, clinical
cell expansion can be improved to provide greater expansion in a single growth period,
direct the phenotypic makeup of expanded populations, and treat more patients faster.
This technology may even reach some cell populations that are not responsive to current
treatments. The aims of this work are focused to identify key material properties that
drive the expansion of T cells and optimize them in the design of a rigidity-based cell
expansion platform.
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1.1 The advent of personalized medicine
Markets for wide-spread therapeutic targets have long enjoyed large focus and invest-
ments over the years. Recently academic researchers, large pharmaceutical companies,
and the government have directed their attention to diseases with smaller affected pop-
ulations, termed personalized medicine. Still regulatory, scientific, and financial chal-
lenges must be addressed before personalized medicine can become widely available.
Cancer is known to be a heterogeneous disease, complex in developmental stages and
effected by innumerable and often unknown genetic and environmental factors. Can-
cers also widely varying in target and manifestation, making current blanket treatment
avenues ineffective and the death rate by cancer relatively constant [Roger et al., 2012].
Even so, cancer accounts for approximately $100 billion in direct healthcare costs, sec-
ond only to cardiovascular disease. Major research in the basic sciences has uncovered
genetic and other molecular mechanistic foundations for more personalized diagnostic
and treatment plans to present the patient with the most appropriate treatment at
the optimal time [Hamburg and Collins, 2010]. The advent of personalized medicine
will see the investment of resources in developing ways in which small factions of broad
diseases like cancer can be addressed more directly, with more appropriate and effective
treatments.
1.2 The immune system functions to fight disease
In a healthy immune system, both adaptive immunity and innate immunity are have
the capacity to launch a response against potential pathogens. While innate immu-
nity is immediately available as a first line of defense to combat a range of pathogens;
it is non-specific, thereby less efficient, and incapable of granting the benefits of im-
munological memory. For these reasons we rely on adaptive immunity. An adaptive
immune response is developed to combat an infection caused by a specific pathogen that
could not be successfully fought off by an innate immune response. Adaptive immune
responses develop over a longer time scale (days rather than hours) but may confer life-
long protective immunity, defense against reinfection by the same pathogen [Janeway
et al., 2001].
Immune cells and other cellular elements of blood originate from the pluripotent
hematopoietic stem cells in the bone marrow. Here a common lymphoid progenitor gives
rise to antigen-specific T and B lymphocytes, central players in adaptive immunity. B
cells mature in the bone marrow while T cells migrate to the thymus for development.
2
After maturation, nave forms of both B and T lymphocytes enter the bloodstream,
bearing a single type of receptor with a unique specificity.
Once a lymphocyte finds an antigen to which its receptor binds, it is then activated
to proliferate and differentiate in a process known as clonal expansion. An adaptive
immune response is initiated when an antigen-presenting cell (APC), often a dendritic
cell, expresses both antigen and co-stimulatory molecules to a nave T cell. Upon the
surface of the APC, specialized host-cell glycoproteins, termed major histocompati-
bility complexes (MHCs), present a small number of foreign peptides among a larger
number of self-peptides. Peptides are so much an integral part of a pMHC’s molecular
structure that they are comparatively unstable when peptides are not bound [Janeway
et al., 2001]. T cell receptors (TCRs) are specific for a unique combination of peptide
antigen and the MHC to which it is bound. These peptide-loaded MHCs are then de-
tected and bound by TCRs to form an interface termed the immune synapse [Monks
et al., 1998, Grakoui et al., 1999, Huppa and Davis, 2003, van der Merwe and Dushek,
2010] (Figure 1.1). The engagement of TCR ligation is accompanied by a co-receptors,
such as CD4, CD8, and CD28. In particular, CD8+ and CD4+ T cells are further
differentiated by the surface proteins they express that confers their ability to recog-
nize different classes of MHC molecules, class I and II respectively. These interactions
prompt the recruitment of Src family kinase lymphocyte-specific protein tyrosine ki-
nase (LcK), which phosphorylates CD3 on at least two immunoreceptor tyrosine-based
activation motifs (ITAMs). Zap70 then binds double-phosphorylated ITAM residues
and is phosphorylated and activated LcK. Once LAT is recruited to the TCR complex,
and phosphorylated by Zap70, further signaling is initiated along an extended protein
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network [Rossy et al., 2012]. In brief, the immune synapse the site where extensive
information is relayed between a T cell and its activating APC. Its highly regulated
and structurally complex method for directing T cells towards one of its multifarious
fates is mediated by the synchronization of interrelated proteins. Depending on the
interaction of other surface receptors, the accepting T cell is programmed to either
target this antigen, as is the case with positive costimulation by CD28, or to ignore this
antigen, which occurs with CTLA-4 mediated antagonism.
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Figure 1.1: Essential signaling components in APC activation of nave CD4+ T cells.
Reprinted from (Murphy 2012).
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Naive T lymphocytes once stimulated undergo differentiation into cytotoxic, helper,
or regulatory T cells. Helper T cells, marked by surface protein CD4+, are the focus of
much of these genetic manipulation and expansion efforts in adoptive immunotherapy.
Unlike CD8+ T cells which are known as cytotoxic T cells because of their role in directly
engaging pathogens; helper T cells instead focus on tasks such as cytokine secretion and
immune cell interactions to direct and hone the response of other immune cells.
Each effector cell will bear receptors specific to the initial offending antigen [Janeway
et al., 2001]. B lymphocytes encounter an antigen and differentiate into antibody-
secreting plasma cells. Immunoglobulins (Ig) are highly specific recognition proteins
produced by B cells that may be surface-bound or secreted to tag or neutralize foreign
antigens. Though a B cell’s antigen receptors are capable of stimulation by free antigens
directly, an optimal response is achieved in cooperation with T cells. A T cell’s antigen-
recognition molecules exist solely as membrane bound proteins. T cell plasticity enables
numerous viable pathways but requires antigen fragment presentation on the surface of
APCs for recognition. If the APC is indeed a B cell, a T cell will activate it to produce
antibody. Likewise if the APC is a macrophage, the T cell can stimulate it to engulf
or destroy the pathogen of interest. This wide range of T cell functionalities can be
usurped and manipulated to the fight against cancer driving the body’s own immune
system.
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1.3 Harnessing the immune system through adop-
tive immunotherapies
The immune system employs a number of processes to detect and neutralize pathogens.
The precarious balance of recognizing foreign pathogens while not collaterally targeting
native tissues comes to light when the immune system fails in either of these two tasks.
Autoimmunity occurs when an immune response is launched targeting native tissues.
Alternatively, proliferation of an undesirable cell population may occur if the foreign
pathogen goes undetected. In efforts to treat autoimmunity and chronic infections,
adoptive immunotherapy, the redirection of immune system resources to address these
insufficiencies, has been explored.
The concept of adoptive immunotherapy was first validated in 1957 but did not see
FDA approval for therapeutic use until 2010 [Spyridonidis and Liga, 2012]. Early im-
munotherapy was based primarily in the introduction of chemical immunomodulators,
including cytokines, interleukins, and chemokines, to stimulate or suppress systemic im-
mune response. In later studies APCs were introduced as ex vivo vaccinations. Of the
APCs, dendridic cells proved to be a promising vector due in part to their high plasticity,
capacity to activated both CD4+ and CD8+ T cells, established markers for immature
and mature states, and ability of cross-penetrations. However, the complexities of the
many considerations associated with dendritic cell use, including but not limited to the
maturation state of the cell, the method of isolation, and the route of administration,
has complicated implementation. Ultimately the complexity of APC manipulation has
led to conceptually sound but practically ineffective therapies, yielding only marginal
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clinical success.
Current achievements in adoptive immunotherapy techniques have been propelled
by technologies such as genetic engineering which have enabled the activation of T cells
in a process that does not require APCs. In fact, throughout a number of clinical
trials T cells have been shown to be responsive to genetic manipulation and expan-
sion for the targeted treatment of cancers [June et al., 2007, Porter et al., 2011]. This
therapy exploits the body’s own defense mechanism: the innate ability of T cells to
detect and respond to foreign antigens with high specificity and sensitivity. Central
to this methodology is the ex vivo expansion of T lymphocytes, wherein cells may be
manipulated in ways not possible in an in vivo scenario. For instance, transfecting cells
with viral vectors or subjecting cells to direct viral infection can be used to encode pro-
duction of chimeric antigen receptors (CARs) or other proteins which confer targeting
abilities [June et al., 2007,Brentjens et al., 2011,Porter et al., 2011,Restifo et al., 2012].
Thus an expansion step is critical to the current implementation of this approach and
stands to greatly benefit from strategic biomaterial design.
1.4 Bead-based cell expansion technologies
In what is considered the clinical gold-standard for cell expansion, patient’s cells are
mixed with small (4.5 mm in diameter) rigid polystyrene beads with magnetic cores,
coated with activating antibodies that induce growth and proliferation, see Figure
1.2. [Kim et al., 2004, June et al., 2007]. In accordance with early clinical trials, a
treatment typically requires purification of T cells from donor or patient blood before
8
cells are transduced with virus for expression of specific antigen expression. These cells
are activated and expanded to reach counts of 3x108 cells (5% transduced) before in-
fusion into the patient over a three day period. Preliminary Phase 1 studies suggest a
patient would require just one such treatments before achieving remission status [Porter
et al., 2006,Porter et al., 2011]. The primary advantage of this cell culture platform is
the increase in surface area afforded by coated beads, over standard culture dishes, to
achieve sufficient expansion. However, the current expansion platform requires removal
of beads from expanded cells through magnetic separation, which is potentially imper-
fect and may lead to the injection [Levine et al., 1998]. An improved ex vivo expansion
platform has the capacity to expand cells from a small or weak population to clinically
relevant numbers quickly, be separated from the culture system easily, and offer better
control over phenotypic output.
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Figure 1.2: In a basic adoptive immunotherapy process, immune cells are isolate from a
patient or another suitable source, expanded ex vivo, and infused back into the patient.
Work by our lab and others has established the effect of substrate rigidity on T
cell activation and expansion; notably, that human T cells activate more readily on
softer (∼100 kPa) PDMS substrates than stiffer substrates (2 MPa). Please see 1.5.1 T
cell mechanosensing for a more indepth discussion [Judokusumo et al., 2012,OConnor
et al., 2012]. To improve upon the current clinical model, our lab successfully pro-
duced beads from both PDMS and NuSil elastomers through an emulsion technologies.
These elastomers possess distinct bulk rigidities ranging from 25 kPa to 2 MPa. NuSil
formulations were employed as they have associated FDA master files to streamline
regulatory considerations if implemented for clinical use. These beads were prepared
for expansion efforts through coating with capture proteins for antibody attachment.
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Protein A and goat-anti-mouse IgG were chosen as early candidates mounted to the
aldehyde on the bead’s surface (Figure 1.3).
Figure 1.3: Elastomer beads are fabricated via curing submerged in albumin. They
are then treated with glutaraldehyde and a capture, or linker, protein before activating
antibodies are mounted.
Protein A was selected for its physiological relevance, a bacterial surface protein
known to bind immunoglobins and is used as an affibody molecule in therapeutic and
diagnostic applications. Goat-anti-mouse IgG offers higher specificity to antibodies
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of interest but is less economically sound. Though goat-anti-mouse IgG bears little
physiological founding, its usefulness is exploited by Miltenyi Biotec’s Anti-Mouse IgG
Microbeads for cell separation. Though beads fabricated from the NuSil polymers were
shown to increase the average number of cell divisions as compared to Dynabeads, no
difference was observed between the elastomer compositions. Recent AFM efforts on
large scale beads fabricated under the same conditions suggest that at a local level all
formulations appear rigid (data not shown). Thus it is desirable to devise a platform
that maintains a large surface area-to-volume ratio but can be cured in air to preserve
rigidity properties during the curing process.
1.5 Improving ex vivo T cell expansion through mechanobi-
ology
1.5.1 T cell mechanosensing
T cells have been shown to sense and respond to their extracellular environment. Recent
investigations have provided direct evidence of force interactions as mediators of TCR
signaling [Kim et al., 2009a,Li et al., 2010]. In particular, the TCR is an aniosotropic
mechanosensor, making it sensitive to tangential or shear, but not normal, forces. Ex-
ternal torque on the TCR following pMHC ligation during immune surveillance was
shown to be necessary for T cell activation; a stop signal was met with a change in
quanternary structure [Kim et al., 2009b]. An increased number TCR-pMHC interac-
tions in a single cell has also been shown to convey a greater degree of T cell response
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specificity and sensitivity [Kim et al., 2009b]. In another study, ITAM in the CD3e
chain was demonstrated to be activated by conformational changes in the ITAM inter-
action with the inner leaflet of the plasma membrane, providing one possible mechanism
by which force may mediate TCR signaling [Xu et al., 2008].
In an alternative model for the study of force-mediated TCR activation, APCs
have been successfully simulated artificially by mounting super-agonists CD3 and CD28
antigens on a rigid surface. Anti-CD3 on the surface binds with the approaching cell,
indirectly triggering the TCR complex, while anti-CD28 provides costimulatory signals
[Shen et al., 2008, Linsley, 2005, Riley et al., 2002]. CD28 co-stimulation in particular
is known to modulate proliferation, differentiation, and effector function in T cells by
regulation of gene transcription, cell cycle progression, survival, secretion of cytokines
and chemokines, metabolism, and mobility [Riha and Rudd, 2010].
Work in our lab shows T cells respond to the mechanical rigidity, here considered
the Young’s Modulus (E), of a substrate presenting anti-CD3 and anti-CD28 [Shen
et al., 2008,Judokusumo et al., 2012]. Recently work published with our collaborators
has demonstrated cytokine secretion, a measure of cell activation, of primary human
T cells correlated with the underlying substrate stiffness. They show that in this cases
softer substrates (E < 100 kPa) stimulate a four-fold increase in cytokine secretion as
compared to stiffer substrates (E > 2 MPa) [OConnor et al., 2012]. Here cytokine
secretion is regarded as a marker of cell activation. These experiments were carried out
on planar Sylgard 184 (Dow Corning) polydimethysiloxane (PDMS) elastomer surfaces.
Mechanical rigidity was altered by adjusting the ratio of the crosslinking agent to elas-
tomer base during substrate preparation. Surfaces were coated in activating antibodies
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prior to cell seeding. Cell viability and activating antibody presentation were shown
to be unaffected by changes in the concentration of crosslinking agent in this rigidity
range.
T cell stimulated on softer substrates not only exhibited higher IL-2 cytokine secre-
tion but also met with greater short term (3 day) proliferation, as measured through a
CFSE assay. These short term proliferation studies are indicators of longer prolifera-
tive performance; and indeed cells stimulated on softer substrates grew over many more
days and incurred a larger number of doublings than those stimulated on more rigid
substrates. Additionally, these studies revealed that softer substrates enhance nave
CD4+ T cell Th1-like differentiation. Rigidity-dependent preferential proliferation and
differentiation of a certain T cell population could be a useful alternative to cytokine-
directed differentiation to meet the needs of clinical applications. Together these data
indicted enhanced activation and expansion as substrate rigidity decreases from 2 MPa
to <100 kPa.
Aside from the direct role of force in TCR/CD3 complex signal-transduction, many
proteins involved in in TCR and costimulatory receptor signal transduction interact
with the actin cytoskeleton, either directly or indirectly [Burkhardt et al., 2008]. More-
over, the structure and dynamics of the actin cytoskeleton, known to respond to changes
in substrate stiffness, have also exhibited an important role at the immune synapse,
supporting and regulating signal transduction [Gomez et al., 2006,Campi et al., 2005].
In fact, tuning of mechanoreceptor function has been attributed to inducible actin
cytoskeletal interactions between TCR and pMHC because the torque will be great-
est in their presence [Yokosuka et al., 2008]. With these early findings, the role of the
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acto-myosin cytoskeleton together with TCR/CD3 complex in force-signal transduction
remains largely uncharacterized. Greater investigation is necessary into the underlying
interactions that between the TCR complex and actin cytoskeleton that produce the
observed rigidity response.
1.5.2 Adaptation of the motor clutch model may explain rigid-
ity response
IThe response of human CD4+ T cells to changes in substrate rigidity was unexpected,
as parallel studies conducted by our lab with murine CD4+ T cells showed a different
trend [Judokusumo et al., 2012]. On gels of Young’s moduli ranging from 10 to 200
kPa activation of primary mouse CD4+ T cells decrease with decreasing rigidities, as
quantified by the IL-2 secreted over six hours and cells attached. The low cytokine
secretion and cell attachment characterizing the softest gel suggest that at this low
range, cell activation is very limited. Additional results in that report of note include
the association of rigidity sensing with CD3 (not CD28) and the inhibition of actomyosin
contractility that through the use of blebbestatin nullified this response. These results
are suggestive of a biphasic response, but inconclusive. More work should be done to
characterize the activation of murine T cells on stiffer substrates (E>200 kPa).
Work in our lab (unpublished data) and others suggest large whole-cell systems are
at work in cytoskeleton remodeling after T cell triggering [Kumari et al., 2014]. We
seek here to establish if functional activation of CD4+ are biphasic, as a part of an
investigation to characterize the response of cell traction forces to substrate rigidity.
The biphasic function of rigidity has been described in a motor-clutch-model put forth
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by Bangesser et al for integrin-ECM interaction [Bangasser et al., 2013]. It is our goal to
determine if this model is adaptable to T cell activation and traction forces are likewise
related to rigidity. The basic components of the motor-clutch model are illustrated in
Figure 1.4, top. Cell traction forces are generated by a set of motors, typically myosin,
that pull on the actin cytoskeleton, which in turn is linked to transmembrane receptors
by molecular clutches. The biphasic response in this model is produced as the bond
off-rate increases with load applied to the system, scaled by a bond rupture force. The
substrate rigidity comes into play as its compliancy may present some elastic resistance
to applied forces, critical for offsetting the traction force and dictating how rapidly
forces are applied to the transmembrane receptors by the moving cytoskeleton.
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Figure 1.4: We can see that for (A) migration and (B) traction forces, the optimal
rigidity range may be cell-type dependent (C) Motor clutch model developed by Odde
and colleauges at the University of Minnesota to explain cell response to rigidity, unlike
other models of its kind it allows for this biphasic response linking the actin cytoskeleton
to transmembrane proteins; (D) Substrate rigidity infuences developing traction and
migration forces with traction force as a function of clutch number, nc, and with number
of motors present nm (from Bangasser 2013). If this model could be applied to T cell
behavior, it would help to reconcile the mechanobiology of the immune system with
other systems.
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As described through this model, at high rigidities bonds load rapidly, increasing
off-rate and decreasing the number of receptors that are engaged at a given time. In
between these extremes, receptors are loaded, yet have sufficient lifespan to generate
strong traction forces. The specific spring constant of the substrate (related to rigidity)
at which this maximum is observed is a function of both motor and clutch parameters,
as well as combinations of these parameters; increasing the number of clutches shifts the
peak to higher spring constant, until a plateau is reached (Figure 1.4, bottom). In the
model adapted to T cell activation, the clutch components are proposed to represent
intermediate adapter and coupling proteins between the TCR complex and the actin
cytoskeleton; it is currently unclear which proteins serve in this mechanical role.
1.6 Impact and significance
Recent advances in genetic engineering have expanded the applicability of adaptive im-
munotherapy techniques. Excitingly, immunotherapy offers an important alternative
for the treatment of diseases that have thus far eluded small molecule pharmacology or
surgical techniques, as is the case for many cancers. Adoptive immunotherapy offers
an alternative treatment strategy by harnessing the high specificity of immune cells.
As it has been shown that these cells can be ‘trained’ ex vivo to meet their physio-
logical targets, the expansion of these trained cells into clinically relevant quantities is
the next major hurdle. Many cell-based therapies in development could benefit from
improved expansion efforts. Immunotherapy comprises a quarter of ongoing clinical
trials of cellular therapies. In 2010, the FDA approved Provenge, a dendritic cell-based
18
treatment for prostate cancer that requires a similar ex vivo expansion process. In
2012, the market for prostate cancer therapeutics reached approximately $17 billion
worldwide. The American Cancer Society estimated more than 240,000 new diagnosis
worldwide [BCCResearch, 2012].
The primary target of this therapy discussed herein is chronic lymphoid leukemia
(CLL), the second most common type of leukemia in adults. The market size of CLL
therapeutics was estimated to be $437 million in 2010 with 123,379 new cases reported
by the World Health Organization [MarketsandMarkets, 2013]. Several recent publica-
tions from our lab and others demonstrate that the activation of T cells is dependent
on the stiffness of the prepared substrate. A critical barrier to the understanding
of T cell mechanosensing is the lack of knowledge of lymphocyte activation on soft
substrates. Elucidating the observed rigidity-based trend from a substrate-dependent
response, considering the implications of a biphasic trend, and exploring the activation
of T cells on rigidity-tuned electrospun mesh has the potential to improve the design
of the clinical expansion platform. We seek to use this improved understanding of T
cell mechanosensing to provide more cells from a single round of expansion and ulti-
mately to exert control over phenotypic makeup of the expanded populations and rescue
exhausted T cells which would otherwise have little therapeutic potential.
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Chapter 2
Polyacrylamide Gels for Delineation
of T Cell Response to Surface
Rigidity
2.1 Abstract
A recent publication by our lab illustrates that murine T cells activate more readily
on polyacrylamide (PA) hydrogels as rigidities from 10 – 200 kPa [Judokusumo et al.,
2012]. Work by a collaborating lab indicates that human T cells trigger on softer PDMS
substrates, where Young’s Modulus is less than 100 kPa as compared to surfaces of 2
MPa [OConnor et al., 2012]. While the range of effective rigidities has been established,
it is important to explore local differences in substrates that may also contribute to these
findings. We must isolate the rigidity-dependence of cell-cell interactions apart from
material properties to optimize design for a clinical cell expansion platform. Though
PDMS is well understood and has found extensive use in cellular engineering, a PA
gel substrate model allows rigidity to be tuned more closely across this specific range
of rigidities and provides control over ligand density and orientation. The objective
of these studies is to delineate a narrow range of optimal substrate rigidities for hu-
man CD4+ T cell activation as a basis for biomaterial design. The approach involves
designing PA gels to meet the rigidity specifications, while incorporating streptavidin
acrylamide to directly bind antibodies in functional positions, required for cell activa-
tion. We seek to determine if human T cell activation is a biphasic response where
TCR triggering, as measured by cytokine secretion, will peak at an intermediate value
of substrate rigidity in the range of 10 kPa to 2 MPa. These rigidity-based trends will
be instrumental in adapting models of mechanobiology to describe T cell activation via
the immune synapse
2.2 Introduction
Isolating human T cell rigidity response is central to determining the effect of material
properties on lymphocyte activation and assessing the propensity and implications of
a biphasic trend. High-level cellular functions have been linked to biphasic responses
with respect to substrate stiffness. In a recent article, Bangasser et al. provides a
concise overview of biphasic responses in mechanobiology and presents a motor-clutch
mechanism as the foundation for this trend. Briefly, this framework captures a biphasic
relationship between traction forces and the rigidity of the underlying substrate. This
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model is based on coupling of transmembrane receptors to retrograde flow of actin
cytoskeleton through a set of clutch connections that show force-dependent changes in
bond lifetime [Bangasser et al., 2013].
This motor-clutch model has been primarily explored in the context of integrin-
based adhesion to extracellular matrix proteins; however, as a complementary system we
believe it may be adapted to describe T cell response to TCR complex ligands. As a first
step, we have explored here whether T cell activation is biphasic with respect to rigidity.
In order to do so, we must separate T cell activation in response to the mechanical
rigidity of the extracellular environment apart from substrate-dependent drivers. It
has long been known that T cells have the capacity to distinguish between soluble and
surface bound agonist antibodies [Geppert and Lipsky, 1987]. O’Connor et al. showed
human lymphocytes activate more readily on softer PDMS substrates, reporting a four-
fold increase in IL-2 cytokine secretion by cells stimulated on surfaces measuring E <
100 kPa over cells stimulated on surfaces measuring E > 2 MPa. PDMS elastomer is
hydrophobic and at a local level comprised of a cross-linked matrix with silica filler that
acts as reinforcement, making fine-tuning of the structural properties that determine
rigidity difficult [Ratner, 2004]. Alternatively, polyacrylamide hydrogels are hydrophilic
and exhibit loose network entanglements at the local level making them less uniform.
Hydrogels are by nature more porous, subject to swelling, and by varying copolymer
ratio rigidity can be controlled down to the tens of kilopascals. Polyacrylamide gels with
a bis-acrylamide crosslinker can be fabricated at 10 kPa to more than 200 kPa [Yeung
et al., 2005,Judokusumo et al., 2012]. Likewise, using a piperazine diacrylamide (PDA)
crosslinker in polyacrylamide gels has been shown to increase the hydrogel rigidity range
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to 200 - 1100 kPa [Yeung et al., 2005,Judokusumo et al., 2012].
The propensity for protein adsorption to a surface is recognized to be highly de-
pendent on both the substrate’s hydrophobicity and electrostatic properties [Nakanishi
et al., 2001]. While PDMS readily adsorbs proteins, early in the study of cell-substrate
interactions it was determined that polyacrylamide hydrogel surfaces do not and there-
fore proteins must be covalently bound to promote cell attachment [OConnor et al.,
2012,Pelham and Wang, 1997]. Initially sulpho-SANPAH was relied upon as a protein
crosslinker for this purpose: covalently linking to the hydrogel under UV exposure and
revealing a N-hydroxysuccinimide ester for primary amine reaction [Tse and Engler,
2010]. Yet modified surfaces used to investigate the immune synapse rely on proper
orientation of antibodies to preserve their functionality [Groves and Dustin, 2003,Moss-
man et al., 2005,Doh and Irvine, 2006,Shen et al., 2008]. In a recent publication, our lab
has developed a system to orient antibodies on a hydrogel surface [Judokusumo et al.,
2012]. Polyacrylamide hydrogels are polymerized from a mixture of acrylamide, copoly-
mer bisacrylamide, and a small percentage of functionalized streptavidin-acrylamide.
The avidin biotin linkage (kd ∼10 - 15) is recognized as one of the strongest noncovalent
bonds, with a lifetime (1/koff) on the order of ∼109 seconds. Once the hydrogel cures,
streptavidin is exposed on the surface and will bind to biotinylated goat-anti-mouse IgG.
Then mouse-anti human CD28.6 and OKT3 activating antibodies can link to the surface
with proper orientation, maintaining their functionality. Antibody density-dependence
and rigidity-dependence have been documented in the study of T cell activation and
proliferation [Judokusumo et al., 2012,OConnor et al., 2012]. Therefore, the concentra-
tion of streptavidin-acrylamide was normalized for each hydrogel formulation to yield
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a standardized surface density of tethered proteins across all substrates.
The aim of this chapter is to examine the rigidity response of human CD4+ T cells
apart from substrate-dependent effects and to use this trend toward reconciling human
and mouse biphasic responses. We developed a polyacrylamide hydrogel platform, with
substrate rigidities ranging from 10 kPa to 1000 kPa. These rigidities were confirmed
through AFM indentation measurements and antibody presentation via streptavidin-
biotin linkages was normalized across all hydrogel formulations. Finally, we examined
the rigidity-dependent activation of nave human CD4+ T cells across prepared hydrogel
substrates.
2.3 Materials and Methods
2.3.1 Preparation of gel substrates
The preparation of polyacrylamide gels, acrylamide solution with a bis-acrylamide
crosslinker, has been previously demonstrated in both this lab and others [Yeung et al.,
2005, Judokusumo et al., 2012]. In accordance with Judokusumo et al. the concentra-
tion of bis-acrylamide can be varied between 0.02% and 0.8% (w/v), to achieve gels
with rigidities ranging from 10 kPa to 200 kPa as confirmed by atomic force microscopy.
In brief, acrylamide and the bis-acrylamide crosslinker are combined and degassed for 1
hour. With the addition of catalyst 10% (w/v) ammonium persulfate (APS) at a 1:100
dilution, polymerization is initiated. Tetramethylethylenediamine (TEMED) is added
at a 1:1000 dilution to enhance bond formation. Streptavidin acrylamide is incorpo-
rated just before gels are sandwiched between coverslips, to limit exposure to oxygen
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which is known to inhibit polymerization, and cured for 2 hours.
These coverslips underwent chemical activation prior to their use. One was function-
alized to promote adhesion and the other was salinized for easy release. To function-
alize, 12 mm glass coverslips were treated with base piranha solution (1:1:5 dilution of
NH4OH:H2O2:diH2O) (Fisher Scientific) and heated at 120oC for one hour to remove
organics. Glassware was then rinsed well with deionized water and submerged in a so-
lution of 5% 3-Aminopropyltriethoxysilane (3-APTS) (Sigma Aldrich) to add primary
amines to the surface. These amine groups were reacted with a 5% glutaraldehyde
solution (Sigma Aldrich), leaving a functional group exposed on the glass to which the
gel binds [Aplin and Hughes, 1981]. Salinization follows a similar procedure, where the
glass was rendered hydrophobic and the gel did not adhere. Large 5 x 7.5 cm glass
slides were first cleaned with base piranha and treated with dimethyldichlorosilane in
5% heptane (Sigma Aldrich), rinsed twice with 100% ethanol, and washed again with
deionized water as a final step. Through the curing process, polyacrylamide binds to
the aldehyde on the surface of the functionalized glass while the salinized surface is eas-
ily removed. To achieve stiffer rigidities as desired, we turned to a new polyacrylamide
gel platform, an acrylamide solution with a piperazine diacrylamide (PDA) crosslinker.
PDA is known to have a higher molecular weight than bis-acrylamide and produce
stiffer gels for use in SDS-PAGE. Adapting a protocol put forth by Hansma et al.,
the concentration of PDA crosslinker is varied from 0.01% to 3% (w/v) to yield poly-
acrylamide gels with rigidities ranging from 100 kPa to 1 MPa [Hansma et al., 2009].
Production of polyacrylamide gels using PDA as a crosslinker can be carried out in the
manner described above; however, 10% APS and TEMED were instead added at 1:200
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and 1:2000 dilutions, respectively. All polyacrylamide gels can be made up to two days
in advance and stored at 4oC in 1x phosphate buffered saline (PBS).
2.3.2 Preparation of antibodies
To assess the uniformity of antibody presentation on the gels, goat-anti-mouse IgG was
biotinylated and fluorescently labeled. A minimum of 100 mL of IgG was vigorously
combined in a 1:8 molar ratio with Biotin X (Life Technologies) and left to react for
1 hour. The solution was dialyzed in PBS for at least 6 hours up to a maximum of
18 hours. It was then removed and combined likewise with a fluorophore, in this case
Alexa Fluor 647 succinimidyl carboxylic acid to label the amines (Life Technologies)
and dialyzed again. For IL-2 surface preparation, the goat-anti-mouse IgG used was
biotinylated but not labeled with a fluorophore, to maximize antibody functionality
and minimize fluorescence channel interference.
2.3.3 Fluorescence analysis of antibody presentation
To assess uniformity of antibody presentation, polyacrylamide gels were incubated with
30µg/mL labeled biotinylated-goat-anti-mouse IgG for 1 hour at room temperature. To
better identify the focal plane of the gel’s surface, samples were then incubated with
200 nm-diameter biotinylated polystyrene microspheres fluorescent at 488 nm; stock
solution 2.8x1012 beads/mL diluted 1:500,000 (Invitrogen).
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2.3.4 Atomic force microscopy
AFM was performed on all gel compositions submerged in 1x PBS. 4.5 µm-polystyrene
spherical tips mounted on 0.35 N/m cantilever silicon nitride probes were purchased
from Novascan (Ames, Iowa) and used in conjunction with a BioScope Catalyst micro-
scope (Bruker Corporation) for data collection. Probes were calibrated to determine
deflection sensitivity, and in turn spring constant, at the start of each experiment.
On average, three indentations per region were performed over four to six regions per
substrate. Analysis was performed primarily in NanoScope Analysis v1.40 (Bruker
Corporation) but code was also written in MatLab (Mathworks, Inc.) for analysis ver-
ification. The Nanoscope analysis provided a consistent and unbiased determination
of the contact point. Other employed functions included a smoothing filter, baseline
adjustment, and accounting for adhesion. The model used to fit indentation curves
was primarily based on the Hertz model, estimating a linear elastic infinite solid and a
round probe that does not undergo deformation.
2.3.5 Cell isolation and culturing
Human CD4+ T cells isolated by Human CD4 T cell Enrichment Cocktail (Rosette
SepTM, STEMCELL TechnologiesTM) from a leukopak (New York Blood Center) are
frozen down until ready for use. In preparation for experimentation, CD4+ T cells were
recovered for 6 to 24 hours at 3x106 cells/mL in RPMI 1640 media supplemented with
10% FBS, 10 mM HEPES, 50 U/mL Penicillin & Streptomycin, 2 mM L-glutamine and
50 µM β-Mercaptoethanol at 37°C and 5% CO2.
27
2.3.6 Interleukin 2 (IL-2) secretion assay
In preparation for experimentation, polyacrylamide gel substrates were incubated in
30 µg/mL goat-anti-mouse IgG for 1 hour at room temperature. However, human T
cells were stimulated with a mixture of monoclonal antibodies targeting the CD3e chain
of TCR and CD28. Therefore, OKT3 and CD28.6 (gift of the Nanomedicine Center
for Mechanobiology) were attached to the IgG linker in a 1:1 ratio to achieve a total
activating antibody concentration of 30 µg/mL. A clean glass coverslip functioned as a
rigid substrate control and was also coated with this antibody mix via direct adsorption.
Nave CD4+ T cells were seeded onto prepared substrates at 3,400 cells/mm2 in sup-
plemented RPMI and maintained under standard cell culture conditions, as described
above, for six hours.
In accordance with the manufacturer’s protocol, cytokine assessment begins at six
hours, a sufficient length of time for cells to initiate IL-2 production. Cells adhered to
their respective substrates were briefly incubated with a catch reagent, which functions
to capture IL-2 yield over the next hour. An APC-conjugated detection antibody was
then added to fluorescently tag secreted IL-2 on the surface of cells. Finally, cells were
fixed with 2% paraformaldehyde. In some cases, fixed cells were stained with Oregon-
green 488 phalloidin (Life Technologies) to facilitate image processing.
2.3.7 Data acquisition and analysis
All images were collected via an Olympus IX81 inverted microscope equipped with 20x,
60x, and 100x objectives. MetaMorph for Olympus software was used to acquire images.
Fluorescence intensity, for both antibody presentation and IL-2 secretion experiments,
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was captured at 20x magnification and quantified via Fiji ImageJ processing package.
For cytokine secretion studies, images were taken in two separate channels: one to
register cell area and locale and the other for the measurement of discrete cytokine
secretion. Analysis of cytokine secretion data was conducted primarily through ImageJ.
Functions of ImageJ used include, but are not limited to: bleach correction of cell
localization channel, threshold, analyze particles, and measure average fluorescence.
In some cases, images of cytokine secretion were analyzed for fluorescence intensity
at cell locations using MetaMorph Software for Olympus (Molecular Devices, LLC),
using brightfield images to determine cell position. For IL-2 cytokine secretion assays,
fluorescence intensity was measured from at least 500 cells per condition, excluding
glass control. The average fluorescence intensity from these cells was averaged.
2.4 Results
2.4.1 Polyacrylamide gels with bis-acrylamide crosslinker lim-
ited in rigidity spectrum
It has been demonstrated by our lab and others that polyacrylamide gels with a bis-
acrylamide crosslinker can be fabricated at rigidities of 10 kPa to more than 200 kPa
[Yeung et al., 2005,Judokusumo et al., 2012]. Based on early observations set forth by
Yeung et al., attempts were made to design stiffer gels by altering the bis-acrylamide
concentration. However AFM indentation measurements prove the limits of this model
and show it unfit for achieving rigidities in the mega Pascal-range (Table 2.1).
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Table 2.1: Polyacrylamide gel compositions with bis-acrylamide crosslinker (n = 8)
2.4.2 Hertzian analytical model employed for AFM indenta-
tion studies
AFM has emerged as a valuable nano-indentation tool to determine the elastic modulus
of both natural and synthetic biological materials [Nitta et al., 2000, Matzelle et al.,
2003, Engler et al., 2004, Solon et al., 2007]. The Young’s modulus for biomaterials
ranging from E < 1 kPa to 100kPa (cells) to E ∼ 1-10 GPa (collagen) has been success-
fully measured using this technology [Dimitriadis et al., 2002, Alonso and Goldmann,
2003, Wenger et al., 2007]. In operation, a laser is focused onto the back face of the
cantilever, on which the tip is mounted, and reflected onto a photodiode detector (Fig-
ure 2.1). To generate a force-distance curve, the position of the scanner is changed in
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the z-direction with repect to the sample, which causes the cantilever to deflect. This
deflection is measured by the change in the laser position on the detector. Collected
data relies on Hooke’s law (F = kh) for interpretation; where the force, F, is calculated
as a product of the deflection h [nm] (h = Z - D, as defined in the schematic) and the
spring constant, k [N/m]. This deflection, h, in practice is a product of the measured
cantiever’s deflection [V] and the deflection sensitivity [nm/V]. Deflection sensitivity is
an important component of the calibration process. It can be computed by pressing a
tip against a rigid surface to relate laser movement on a position-sensitive split photo-
diode detector to probe motion. This constant allows future deflections (on surfaces of
unkown rigidities) to be measured directly from the laser’s position on detector.
Determination of the spring constant is also required for proper calibration. Hutter






k 〈z2c 〉, where kB is the Boltzmann constant, T is the absolute
temperature, and 〈z2c 〉 is the mean squared displacement of the cantilever’s thermal
motion [Hutter and Bechhoefer, 1993,Ohler, 2007]. The spring constant is then applied
to Hooke’s law, as previously mentioned, and when given a deflection a force can be
calculated.
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Figure 2.1: A) Basic schematic of AFM indentation system. (B) Resulting ‘force-curves’
where cantilever deflection is plotted against probe position. (C) Example of a curve
(blue) measuring approximately 10 kPa by Hertzian approximation (green); red lines
denote range of measurement and dashed blue vertical line approximates contact point.
(D) Example of a curve measuring approximately 1000 kPa by Hertzian approximation.
Reprinted from Costa 2006.
The Hertz model is often used to approximate indentations in biological samples. It
assumes a linear elastic solid and a spherical, not deformable tip. The Hertzian model














, where R is the radius of the sphere, E
is the Young’s Modulus, a is the radius of the contact circle, and n is Poisson’s ratio
(value of 0.5 for most soft biological samples) [Lin et al., 2007]. This model assumes
infinitesimal sample thickness and homogeneity of substrate material which, though
widely implemented, may not be the case for biological samples such as cells which can
be thin and heterogenic.
Alternative models have been developed to better account for the variability of AFM
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data collected from soft materials and biological samples. Interestingly, the Derjaguin,
Muller, Topov (DMT) model, published in 1975, may be applied to tips with a small
curvature radius and high stiffness, in the investigation of samples with low adhesive
properties. It differs from the Hertzian model primarily through its consideration of
the Van Der Waals forces acting along the perimeter of the contact area. These forces
increase the level of attraction between the probe and sample; thereby weakening elastic
repulsion forces [Cappella and Dietler, 1999]. Additionally, Costa et al. devised a new
theory to address cell indentation experiments based on finite element modeling to
account for indenter geometry [Costa and Yin, 1999]. This model may be simplified for
the case of linear hyperelastic materials to read F = 4
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model facilitates the computation of elastic modulus as a function of indentation depth
which reveals information regarding nonlinearity and heterogeneity of the sample.
Results from the following AFM indentation studies were analyzed primarily via
the Hertzian model, the most widely used in studies of biological samples. Again
this model assumes infinite sample thickness and homogeneity of substrate material
indented with a spherical, non-deformable tip. Polyacrylamide hydrogels are considered
homogenous, with small pore sizes. Samples for both indentation analysis and cell
activation studies were prepared on 12 mm-diameter coverslips with a minimal volume
of 15 mL. Basic mathematical computations lead to a calculated total volume of 15 mm3
and a conservative gel height of approximately 130 mm. In order for a sample to be
considered infinitely thick, indentation testing must occur in less than the top 10% of
the entire sample depth [Costa and Yin, 1999]. Typical AFM measurements performed
indent 300 nm – 2 mm into the surface of the gel, well within this restriction, so we may
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therefore consider the sample infinite. Finally, measurements were performed with a
spherical polystyrene tip, much more rigid than the hydrogels with which they interact
and may therefore be considered non-deformable.
Exploring these different analytical models across the same data set, as we will see
later in Table 2, the theory detailed in Costa et al. gave similar results to the Hertzian
model at low rigidities and increasingly disparate values at higher rigidities. This may
be explained by the Costa model’s accounting indentation depth for small biological
samples. This work examined indentations up to 80% of the thickness for thin samples
(< 2 µm). It states that for small values of indention depth, the model performs well;
however, at deeper indentations artifacts from an underlying rigid substrate appear.
Our samples have not been indented to the same degree, nor do they suffer from finite
depth. For more rigid substrates we can assume a smaller indentation depth. As a
comparison, indentation depths hold a polynomial relationship to the Young’s Modulus
through Costa’s formula in which at low indentation depths only slightly higher rigidi-
ties are observed. Alternatively as indentation depth decreases in the Hertz model,
deflection increases leading to a proportional increase in force and thereby Young’s
Modulus.
Differences in the Hertz model conducted through the Nanoscope software and via
MatLab code can primarily be explained by the identification of the contact point for
each curve. The contact point may be most simply defined as the explicit point where
the approaching tip makes contact with the substrate. Though this may seem simple
enough to identify in an ideal scenario, the selection of this point may be complicated
in reality by a drifting baseline, a noisy signal, and intramolecular forces between the
34
tip and the substrate, as is the case for DMT. The Nanoscope software provides for
smoothing the curve, adjusting for baseline trajectory, and employs a sophisticated
algorithm for selecting the contact point. Here we saw that the Hertzian modeling
carried out through MatLab was slightly lower (by a factor of two or less) than that
via Nanoscope, but may be presumed, for these reasons, to be less accurate. Like-
wise results from DMT analysis showed gels appear less rigid; this is undoubtedly due
to DMT’s attributing some of the force to surface energy. The DMT model assumes
forces acting outside of the contact region create a finite area of contact between tip
and sample for the duration of the indentation. Though polyacrylamide gels exhibit
low adhesive properties, the large spherical tip employed here does not fit well with the
DMT model.
2.4.3 Polyacrylamide gels with piperazine-diacrylamide crosslinker
can be made from 100 kPa to 1 MPa
As polyacrylamide gel compositions with bis-acrylamide crosslinker failed to meet the
desired rigidity range (10 kPa to 1000 kPa), an alternative crosslinker was chosen.
Hansma et al, 2009 describes employment of piperazine diacrylamide (PDA), a crosslinker
that can be substituted for bis-acrylamide directly, replacing mass for mass, without
changing polymerization protocols (Figure 2.2) (Bio-Rad bulletin). PDA has been sub-
stituted for bis-acrylamide in electrophoresis work to increase gel strength and reduce
background in silver staining. It has also been used to increase resolution and improve
sensitivity in protein sequencing gels.
35
Figure 2.2: The stable piperazine ring characteristic of PDA eliminates hydrogen atoms
of amide groups and contributes to the increased rigidity of polyacrylamide gels. MW
PDA 194.23 and MW bis 154.17
Importantly, this crosslinker has been shown to achieve hydrogels in a rigidity range
from 200 to 1100 kPa, as measured by nanoindentation [Hansma et al., 2009,Allen et al.,
2012]. It has been previously observed that AFM indentation will yield slightly lower
rigidity measurements than those via nanoindentation [Hansma et al., 2009]. PDA gels
were fabricated in accordance with Hansma et al. and measured via AFM indentation
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(Table 2.2). It is evident from these early studies that through the use of PDA as a
crosslinker polyacrylamide gels can be produced at sufficiently high rigidities, in the
mega-Pascal range. Alternatively it also establishes a need for designing PDA-based
gels at the softer end of the rigidity spectrum of interest (10-100 kPa).
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Table 2.2: Early AFM indentation measurements analyzed via distinct prescribed
model. All results expressed in kilopascals. Three measurements were taken from
six regions per sample. Average are representative of successful indentations.
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Compositions described in Table 2.3 were designed to elicit softer rigidities. Decreas-
ing the percent of crosslinker does produce less rigid gels; however, PDA concentration
and rigidity do not hold a linear relationship. These results point to the lower limit
of the PDA-polyacrylamide gel system: at low concentrations of crosslinker, approxi-
mately 100 kPa gels are the softest achievable.
Table 2.3: Early PDA-polyacrylamide gel formulations to establish lower end of rigidity
range
As previously mentioned, it would be most desirable to establish a hydrogel substrate
system with a singular crosslinker to span the desired rigidity range (10 kPa – 1000
kPa); however, neither polyacrylamide gels formulated with bis-acrylamide nor those
formulated with PDA span the desired range. Therefore a system in which the two
types of preparations overlap to map the entire range is utilized. The final working
compositions of hydrogels used throughout this study are given in Table 2.6.
While we have put a hydrogel system in place that allows for cell seeding across
the desired range of rigidities, we must also consider that the presentation of anti-
bodies on the surface will also play a causal role in T cell activation. As previously
mentioned, polyacrylamide hydrogel substrates do not readily adsorb proteins. Our
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lab has developed a system that not only covalently binds proteins to the surface but
also ensures their proper orientation, an important stipulation in antibody presenta-
tion where functional binding sites are paramount to cell activation [Judokusumo et al.,
2012,Groves and Dustin, 2003,Mossman et al., 2005,Doh and Irvine, 2006,Shen et al.,
2008]. In this system, streptavidin-acrylamide replaces a portion of the deionized water
concentration in the gel solution, as streptavidin-acrylamide is primarily composed of
streptavidin protein not acrylamide. Streptavidin-acrylamide present at the surface of
the gel binds and thereby properly orients biotinylated goat-anti-mouse IgG.
To ensure uniform antibody presentation, biotinylated goat-anti-mouse IgG was la-
beled with a fluorophore and incubated on the surface of several different rigidities
across both gel-types. To improve proper identification of the hydrogel surface upon
imaging, these samples were also incubated with biotinylated polystyrene microspheres,
fluorescent in an alternate channel. In following previously established protocols by
Judokusumo et al., a total concentration of 667 mg/mL streptavidin-acrylamide was
used for all gels with expected rigidities greater than or equal to 100 kPa. For lower
rigidities, 267 µg/mL streptavidin-acrylamide was employed. Early work at these con-
centrations showed low expression rates with non-uniform antibody presentation for
PDA-crosslinked gels (Table 2.4).
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Table 2.4: Fluorescence measurements denoting antibody presentation on polyacry-
lamide hydrogels’ surfaces. Average intensity calculated from twelve images with mea-
surements across nine distinct regions in each image. Standard error represents variation
over one sample.
Antibody presentation on PDA gels was deemed adequate due to fluorescence in-
tensity measurements and preliminary cell cytokine secretion studies (data not shown
here). Therefore streptavidin acrylamide concentration was lowered in bis-acrylamide
hydrogels to approximate the fluorescence antibody presentation in PDA hydrogels.
Adjusted streptavidin acrylamide concentrations are given in Table 2.5, along with
their measured fluorescence intensity.
Table 2.5: Adjusted streptavidin acrylamide concentrations to yield uniform fluores-
cence intensities across gels. Average intensity calculated from twelve images with
measurements across nine distinct regions in each image. Standard error represents
variation over one sample.
Similar fluorescence intensity values across all samples reflect equivalent antibody
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presentation across all substrates. However, PDA-based hydrogels have a less uniform
presentation pattern than their bis-acrylamide counterparts. To account for such vari-
ation, 100 kPa and 200 kPa samples from both bis-acrylamide and PDA-crosslinker
formulations were included in future studies.
The incorporation of streptavidin acrylamide into polyacrylamide does not signifi-
cantly alter measured gel rigidity, evident in Table 2.6. PDA-crosslinker concentrations
were determined by interpolating measurements displayed in Table 2.2. Streptavidin
acrylamide was incorporated in place of deionized water in each of the formulations.
Table 2.6: Adjusted streptavidin acrylamide concentrations to yield uniform fluores-
cence intensities across gels
These are the final working compositions of hydrogels used in human nave CD4+ T
cell cytokine secretion studies.
2.4.4 Human CD4+ T cells activate across rigidity range
IL-2 secretion assay (Miltenyi Biotech) was performed to detect cytokine secretion. IL-2
cytokine secretion is a key indicator of early CD4+ T cell activation and regulates and
functionally mediates the activity of other leukocytes [Fraser et al., 1991,Street et al.,
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1990].
Human nave CD4+ T cells were seeded on prepared hydrogel substrates presenting
a 1:1 mix of anti-CD3 and anti CD28.6. After cells have been incubated on substrates
for six hours, IL-2 cytokine secretion is measured to quantify the rate at which it is
produced. This cytokine secretion kit indirectly captures IL-2 production via the abun-
dant transmembrane protein CD45, which enables discrete measurement of secretion
on an individual cell level. The cytokine secretion assay is a fluorescence-based surface
capture kit and experimental results are quantified through fluorescence microscopy
(Figure 2.3).
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Figure 2.3: Rigidity dependent activation of T cells measured by IL-2 secretion at 6
hour time point. (n = 1).
Cells exhibit higher IL-2 secretion on softer substrates nearest to 100 kPa over more
rigid substrates. T cells also evince lower cytokine secretion on substrates softer than
100 kPa, trends characteristic to a biphasic response. Cells secrete higher levels of
cytokine on bis-acrylamide formulations as compared to PDA formulations, which may
be due to a combination of material properties unique to each or the uniformity of
antibody presentation on the surface. However the trend across rigidities fabricated
from each crosslinker formulation is consistent.
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2.5 Discussion
Studies examining rigidity-based activation of T lymphocytes have been vital to the
increased understanding of immune cell function and are taking a central role in to the
development of improved therapeutics for clinical trials [OConnor et al., 2012]. The
work in this chapter demonstrates a new platform for T lymphocyte rigidity-based ac-
tivation studies, based on polyacrylamide hydrogels formed with a PDA crosslinker.
PDA was selected as a crosslinker because it is known to be biocompatible and produce
stiffer hydrogel substrates than the use of a bisacrylamide crosslinker. Moreover PDA
can be easily integrated into the original hydrogel system; the manufacturer recom-
mends replacing bisacrylamide with PDA on a gram-by-gram basis.
These polyacrylamide gels with PDA crosslinker were tested alongside previously
characterized polyacrylamide gels with bisacrylamide crosslinked [Judokusumo et al.,
2012]. AFM indentation measurements were primarily analyzed through the Hertz
model. This model assumes a linear elastic substrate indented by a spherical tip that
is not deformed under contact. Futhermore it assumes infinitesimal sample thickness
an homogeneity of the substrate material. These assumptions hold up well within this
system: a rigid polystyrene spherical tip interacts with a comaratively soft homogeneous
polyacrylamide gel substrate, never indenting to a depth more than 10% of the total
height of the gel so that it may be considered infinitely thick.
This new platform stimulated T cell activation in agreement with results published
by O’Connor et al. Cells secrete higher levels of cytokine on soft substrates (100 kPa)
as compared with rigid substrates (1000 kPa). These results provide clear evidence of
the importance of a substrate’s mechanical properties independent of material type.
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One explanation set forth suggests that these forces impact the formation and stability
of the immune synapse and in turn modify signal transduction downstream, but much
of T cell mechanosensing pathways remain unknown.
Though changes in the stiffness of the substrate on which the antigens are presented
would be expected to dampen the forces applied to individual adhesive receptor-ligand
interactions, the range of force required to induce activation or disrupt the mechanical
linkage between the TCR and APC remains unknown [OConnor et al., 2012]. Softer sub-
strates may benefit from smaller applied loading forces. Lower applied forces translate
into extended bond lifetime and prolongation of signaling [Evans, 2001]. Unfortunately,
the technology to examine dynamic signaling in live cells on such a small spatial scale
is severely limited.
The forces generated on the T cell or by the immune synapse itself directly impact
T cell activation. In fact, the cytoskeleton is known to exhibit mechanical coupling
with the TCR complex and mechanical forces applied to the TCR complex through an
anchored pMHC or anti-CD3 activating antibody initiate TCR signaling [Nguyen et al.,
2008, DeMond et al., 2008, Yu et al., 2010, Ma et al., 2008, Li et al., 2010]. Through
the work in this chapter we have determined that human T cell activation is biphasic
with respect to rigidity. These results will facilitate future efforts in reconciling the
trend exhibited by mouse cells into a single and unified framework adapted from the
motor-clutch model. This model will aid ultimately in identifying specific molecular
pathways that mediate T cell mechanobiology.
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Chapter 3
Electrospun Mesh Platform for
Enhanced T Cell Expansion
3.1 Abstract
The ex vivo manipulation of T cells and introduction, or at times re-introduction, into a
patient has emerged as a new tool in immunotherapy. A major challenge associated with
this transition is producing a highly controlled and expedited expansion of these cells to
reach a clinically relevant population size. The current clinical gold-standard for T cell
expansion utilizes rigid (Giga Pascal) antibody-coated Dynabeads® CTS polystyrene
beads in combination with an in-bag format, WAVE bioreactor (GE LifeSciences) to
provide increased surface area per cell volume as opposed to standard culture dishes.
This system evolved from a system for lymphocyte isolation and purification where cells
attach to magnetized beads which can then be separated from solution. Though widely
accepted and implemented, this expansion system presents difficulties in manufacturing
and use. Notably, the separation of cells from beads prior to reinjection into the body
is known to be incomplete and the implications of the accumulation of these plastic
particulates in the blood stream are unclear.
Here we describe a soft-material, fiber-based system with particular focus on main-
taining the mechanical properties of polydimethylsiloxane (PDMS) to exploit rigidity-
based expansion trends presented in the previous chapter, while easing risks associated
with bead-cell separation and maintaining a large area-to-volume ratio. Exposing T
cells to electrospun mesh of varying rigidities, fiber diameters (on the order of micro-
to nano-meter), and mesh densities over short (3 day) and long (15 day) time periods
have allowed for an improved understanding of cell-fiber interaction and contributed
to the iterative design of this expansion platform. Results from this study provide a
new insight into how micro- and nano-scale topography features of a biomaterial affect
T cell activation and functional differentiation. Furthermore the outcome of this work
provides clues into the feasibility and advantages of a stable rigidity-based expansion
platform for clinical use.
3.2 Introduction
Recent advancements in adoptive immunotherapy have generated a need for a platform
with which to expand cells from a limited population to reach clinically relevant num-
bers. These naive T cells are initially isolated from the whole blood of the patient or
other source and exposed ex vivo to activating antibodies, typically over three days’
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time. During this incubation period, T cell surface receptors interact with antibodies
on the surface which initiaties cell activation. As the T cells activate they lift off of the
coated substrate, undergo division, and differentiate. It is through this dividing and
differentiating that T cells are commissioned to recruite other players in the immune
response. Depending on the successfulness of the initial activaiton, these cells may
continue to divide over several days or weeks in culture.
Dynabeads, the current clinical gold-standard, are mixed with purified T cells and
typically achieve 6 doublings in 10 days. The beads are then collected with a magnet
before cells are infused into the patient, a process which is known to be incomplete
[Levine et al., 1998]. Additionally, human lymphocytes have been shown to achieve
greater expansion on softer (<100 kPa) PDMS substrates [OConnor et al., 2012]. Work
by our lab has successfully produced beads from both PDMS and NuSil elastomers
through an emulsion technology (unpublished data). NuSil formulations have associated
FDA master files to streamline regulatory considerations. These elastomers possess
distinct bulk rigidities ranging from 25 kPa to 2 MPa. Though these beads were shown
to increase the average number of cell divisions as compared to Dynabeads, no difference
was observed between the elastomer compositions. Recent AFM efforts on large scale
beads fabricated under the same conditions suggest that at a local level all formulations
appear rigid (data not shown). Thus it is desirable to devise a platform that does not
require an emulsification agent for submerged curing. Please refer to 1.4 Bead-based cell
expansion for a more detailed overview of developing technologies for T cell expansion.
Within this chapter we describe the characterization of a stationary expansion system
comprised of an electrospun platform that maintains a high surface area-to-volume
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ratio. Electrospun polymer mesh networks have been produced with extensive surface
area for cell expansion [Kim et al., 2009b, Kim et al., 2012]. Current electrospinning
techniques enable customization of fiber diameter and porosity that, together with
chemical functionalization, tailor extracellular matrix conditions to support growth and
activation for a variety of cell types [Yoo et al., 2009,Bhardwaj and Kundu, 2010,Saino
et al., 2011]. This platform not only capitalizes on the observed rigidity response
exhibited by human T cells but also simplifies the process of substrate removal from the
system. This electrospun mesh format has allowed for control over the modification of
particular parameters targeting polymer composition, fiber diameter, and mesh density
to effect local rigidity and small-scale topography, conditions known to influence cell
activation. We are primarily interested in the local rigidity perceived on a cellular level
and the influence of topology, including fiber diameter and pore-size, in determining
the success of cell expansion. Mesh was designed from the following polymer blends of
PDMS and polycaprolactone (PCL): 10:1 PDMS blended 1:1 with PCL (10:1/1:1), 10:1
PDMS blended 4:1 with PCL (10:1/4:1), 50:1 PDMS blended 1:1 with PCL (50:1/1:1),
and 50:1 PDMS blended 4:1 with PCL (50:1/4:1). Mesh was also spun from PCL
without PDMS. In order to gain a better understanding of T cell response to topology,
in some instances both nanometer- and micrometer-diameter fibers were spun from the
same compositions. Likewise, aligned and unaligned fibers were also procured from the
same blends.
In order to assess mesh performance, we began by characterizing mesh rigidity on
a local level. Using a 4.5 µm-diameter polystyrene tip to approximate the size of a 7
µm-diameter T cell, we gathered indentation measurements via AFM. These rigidity
50
measurements do not reflect classical material properties, but rather describe the surface
as perceived by the T cell. We are also particularly interested in exploring how topology
of the mesh influences cell expansion; therefore work was undertaken to characterize
cell-mesh interaction through confocal microscopy. Finally, both short (3 day) and long
(15 day) term cell proliferation studies were conducted on prepared mesh in order to
assess their overall propensities for T cell expansion.
3.2.1 Electrospun mesh
Developed initially for the fabrication of non-woven textiles, electrospinning technology
has more recently been adapted to a variety of natural and synthetic polymers for use
in tissue scaffolding [Friess, 1998, Li et al., 2002, He et al., 2007], dressings for wound
healings [Jin et al., 2002,Khil et al., 2003], drug delivery [Kenawy et al., 2002,Zong et al.,
2002, Zhang et al., 2006], immobilization of enzymes [Jia et al., 2002, Ye et al., 2005],
biosensing [Haiying et al., 1996,Zhang et al., 1998,Zhang, 1998], and filtration [Endres
et al., 2003,Burger et al., 2006]. These applications utilize a basic electrospinning system
that consists of a high voltage power supply, a spinneret, and a grounded collector
plate [Liang et al., 2007,Sill and von Recum, 2008]. In this process, a polymer-solvent
mixture is extruded through this charged syringe, linked to the high voltage power
supply (Figure 3.1 ). When the repulsive electrical forces overcome the surface tension
forces in the stream, a charged jet of polymer solution is ejected from the tip of the
Taylor cone and accelerated towards a grounded plate. As the stream of solution is
rapidly whipped in the space between the syringe tip and the collector, the solvent
is evaporated and the polymer is collected as a randomized mesh network [Taylor,
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1969,Adomavičiūtė and Milašius, 2007]. Importantly, processing parameters, including
but not limited to flow rate, applied voltage, and makeup of the polymer solution, may
be manipulated to generate particular geometrical and structural properties within the
scaffold [Demir et al., 2002, Zeng et al., 2003, Sill and von Recum, 2008, Zhang et al.,
2005,Zhao et al., 2005].
Figure 3.1: Schematic of electrospinning technique. Fibers are extruded onto a
grounded collector by applying a high voltage to the tip of a syringe filled with a
polymer solution. Reprinted with permission from [Bhardwaj and Kundu, 2010].
Several groups have demonstrated that immune murine cells can be isolated and/or
activated on electrospun fibers. Interestingly, Saino et al. observed that macrophages’
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secretion of proinflammatory molecules depended on PLLA fiber diameter but not fiber
orientation [Saino et al., 2011]. However, no available platforms have been optimized
based on T cell substrate rigidity and they do not fully meet the needs of long term
clinical human T cell expansion. Kim et al. have successfully isolated and activated
CD3+ T lymphocytes with magnetized nanoparticles spun into polymer fiber [Kim
et al., 2012]. However, as the fibers must be collected via magnet post-expansion,
this technology does not ensure the complete elimination of polymer particulates and
therefore presents many of the same concerns at the current Dynabead cell expansion
model.
For substrate production we have collaborated with the Biomaterials and Interface
Tissue Engineering Laboratory under the guidance of Dr. Helen H. Lu at Columbia
University to electrospin mesh from a blend of PCL and PDMS elastomers. We as-
sert that the rigidity of electrospun mesh will depend on polymer composition, fiber
diameter, and mesh porosity. To address this first point, perceived surface rigidities
were targeted by formulating polymer solutions with a range of bulk stiffnesses that
we aim to preserve in fiber format. It is challenging to electrospin PDMS fibers owing
to PDMS’s low molecular weight [Yang et al., 2009]. However, it has been success-
fully electrospun after blending with copolymers including poly(methyl methacrylate)
(PMMA) [Yang et al., 2009] and polyvinylpyrrolidone (PVP) [Srivastava et al., 2007],
which not only increases the chain entanglements of the polymer but also confers other
attractive properties such as thermal stability, mechanical strength, and surface prop-
erties. Known for its biocompatibility, PCL was chosen as a copolymer for electrospun
nanofibers [Chong et al., 2007]. PCL is widely used in drug delivery applications owing
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to its slow biodegradation by hydrolysis of its ester linkages [Sinha et al., 2004].
As mentioned above, a variety of PDMS-PCL fiber formulations have been developed
and tested. PDMS is made in-house by our collaborators combining a polymer and
crosslinker at two particular ratios. The two formulations have been chosen for their
range of bulk rigidities: 1:10 PDMS exhibits a bulk rigidity of approximately 2 MPa
while the bulk rigidity of 1:50 PDMS measures >100 kPa [OConnor et al., 2012]. Both
of these PDMS ratios are blended in either 4:1 or 1:1 ratios with PCL, in efforts to
preserve their individual rigidities, and spun into mesh. These polymers are combined
in a solvent phase together with a 3:1 ratio of DCM and DMF, to achieve a final polymer
concentration of 19% w/v in solvent for the production of fibers with nanometer-scale
diameters and of 35% w/v for the production of fibers with micrometer-scale diameters.
FTIR spectroscopy confirms proper incorporation of both PCL and PDMS polymers
in fiber formulations (data not shown). PCL, known to have very stiff bulk properties,
was also electrospun without PDMS to achieve a broader range of rigidities.
Scanning electron microscopy (SEM) is employed for surface mapping and morphol-
ogy assessment. Additionally, mesh stiffness and protein penetration are measured to
project expansion capacity of fabricated scaffolds. The surface topography of a number
of mesh compositions is captured via SEM and illustrated in Figure 3.2 Images depict
a randomized (unaligned) mesh network for each formulation.
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Figure 3.2: SEM images of samples from a number of PDMS-PCL mesh, with diameters
ranging from nanometer- to micrometer- scale diameters.
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Morphological data from electrospun mesh can also be collected from SEM images
(Table 3.1). Notably, PCL spun alone under the same conditions as PDMS-PCL formu-
lations presents wider fiber diameters and higher bulk rigidities, as expected. Addition-
ally, by increasing the percentage of polymer in solvent, larger, micrometer-scale fiber
diameters are achieved. However none of the pore sizes appear large enough to foster T
cell penetration, as the diameter of a lymphocyte is known to measure approximately
7 µm.
Table 3.1: Morphological data of mesh formulations collected via SEM images together
with mechanical properties derived from Instron measurements, p < 0.05.
In addition to an investigation of morphological properties, electrospun mesh also
underwent mechanical testing. Samples were tested to failure under uniaxial tension
on an Instron mechanical testing device. Tensile testing showed inherently rigid bulk
properties, in the mega Pascal range (Table 3.1). A one-way ANOVA was conducted
across each material property using a Tukey-Kramer post-hoc test for pair-wise com-
parison of each group. Formulations comprised of a blend of PDMS and PCL gives
softer moduli and thinner fibers than PCL alone, as denoted by the asterisk. For more
details regarding mesh fabrication and material characterization, please see appendix.
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3.3 Materials and Methods
3.3.1 Atomic force microscopy
AFM was performed on all mesh compositions. Small pieces of mesh were cut with foil
backing and secured foil-side down to a petri dish. Mesh was incubated for 2 hours
at ambient temperature in 2-5% bovine serum albumin for two hours to prevent adhe-
sive interactions during indentation. The samples were rinsed thoroughly before being
submerged in 1x PBS for measurement. 4.5 mm-polystyrene spherical tips mounted on
0.35 N/m cantilever silicon nitride probes were purchased from Novascan (Ames, Iowa)
and used in conjunction with a BioScope Catalyst microscope (Bruker Corporation) for
data collection. Probes were calibrated to determine deflection sensitivity, and in turn
spring constant, at the start of each experiment. On average, three indentations per
region were performed over four to six regions per substrate. Analysis was performed
primarily in NanoScope Analysis v1.40 (Bruker Corporation). Functions used in anal-
ysis include smoothing filter, baseline adjustment, and accounting for adhesion. The
model used to fit indentation curves was primarily based on the Hertz model, estimating
a linear elastic infinite solid and a round probe that does not undergo deformation.
3.3.2 Surface preparation
Electrospun mesh was removed from foil, mounted on 12 mm coverslips with 1:3 PDMS
(crosslinker: polymer ratio), and left to cure at ambient temperature for >1 day. After
curing was complete, excess mesh was trimmed from the edge of the coverslip. Prior to
the experiment, both sides of the mounted mesh were sterilized in ethanol under UV
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and then dried completely in a sterile culture hood. Mounted scaffolds are compatible
with 24-well polystyrene dishes for long-term cell expansion experiments. For confocal
imaging, mesh was taped to glass coverslip backings to allow for removal and improve
ease of handling.
3.3.3 Confocal microscopy
Images were collected via a LEICA TCS SPS Confocal and Multiphoton Microscope
with 20x objective at zoom 0 or 5, for a total magnification of 20 – 100x. Leica
Application Suite Advanced Fluoresence (LAS AF) software was used to acquire images.
For confocal imaging, electrospun mesh was taped to coverslips and labeled with Alexa
Fluor 647 donkey-anti-mouse IgG (Life Technologies) and unlabeled OKT3 and CD28.6,
while cells were labeled with CFSE CellTrace (Life Technologies) prior to seeding. For
mesh visualization studies, images were taken in two separate channels: one to visualize
penetration of antibodies in the scaffolding and the other to locate and identify the
penetration of T cells into the mesh. Analysis of images and reconstruction of stacks
were primarily performed through Fiji ImageJ software package.
3.3.4 Cell culture
Human CD4+/CD8+ T cells were isolated from a leukopak source (New York Blood
Center) via Rosette Sep Human T cell Enrichment Cocktail (Stemcell Technologies) and
were frozen down until ready for use. In preparation for experimentation, CD4+/CD8+
T cells were recovered for 6 hours at 3x106 cells/mL in RPMI 1640 media supplemented
with 10% FBS, 10 mM HEPES, 50 U/mL Penicillin & Streptomycin, 2 mM L-glutamine
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and 50 mM b-Mercaptoethanol at 37oC and 5% CO2.
3.3.5 Assessment of initial cell-mesh binding
Cleaned mesh were incubated in 2 µg/mL of goat-anti-mouse IgG or 100µg/mL Protein
A, a protein linker which binds to the prepared substrate by direct adsorption for
two hours at room temperature. In early studies, mesh were directly subjected to
a mixture of antibodies, but as the system was refined, a 5% bovine serum albumin
incubation (BSA) step was added. After a thorough washing, scaffolds were then coated
with OKT3 and CD28.6 which bind to the IgG linker. These antibodies were used in
a 1:4 ratio, respectively, to achieve a total activating antibody concentration of 100
µg/mL. Following thaw and 6 hour recovery, CD4+/CD8+ cells were seeded at 1,000,000
cells/mL in a 1 mL volume per well. At 2 hours post-seeding or at 12 hours post-seeding,
unbound cells were gently removed from the substrate and counted via hemacytometer
to determine the percentage of cells initially adhered to the substrate, with the potential
for stimulation and activation, at these early time points.
3.3.6 Long-term cell expansions in conjunction with CFSE as-
says
Mesh were prepared with protein linker, BSA block, and activating antibodies as de-
scribed previously. Following thaw and 4.5 hour recovery, CD4+/CD8+ nave T cells
are stained with carboxyfluorescein succinimidyl ester (CFSE), a fluorescent dye that
is retained stably within the cells for long periods, even through several divisions. Cell
proliferation can be measured by assessing the halving of conferred fluorescence within
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daughter cells after each division. Therefore, cell populations were assessed for the per-
centage of cells divided and proliferation index, the average number of divisions each
original cell underwent.
After staining, cells were seeded onto prepared mesh at 1,000,000 cells/mL, a density
equivalent to approximately 5,670 cells/mm2. The positive control was comprised of an
equivalent number of cells incubated with 3x106 Dynabeads (Life Technologies), consid-
ered the clinical gold standard of T cell activation. This concentration was calculated
to equate the available surface area on PDMS beads in other rigidity-based expansion
studies. A negative control consisting of unstimulated cells was also included.
After three days, cells were washed from the mesh, counted, and diluted to 800,000
cells/mL for optimal growth conditions. A portion was removed for CFSE analysis via
flow cytometry. Cells were counted and suspended at the prescribed density every other
day thereafter. CFSE analysis was carried out on both Day 3 and Day 5.
Cell population doublings were calculated using the following equation,
T1 = T0e
D (3.1)
where T0 is the initial cell count before the growth period, T1 is the final cell count after
the growth period, and D is the number of doublings. To account for large cell volumes,
we considered D to be the increase factor and did factor in dilution by considering the
total volume, VT , and the volume kept in culture Vc as T1 = T0 (Vc/VT ) e
D. The total
number of doublings was calculated by taking the log of the product of the increase
factors for each day up until that day.
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3.3.7 Flow cytometry
After three days, cells were washed from the mesh and a small portion was analyzed
through flow cytometry (BDFACS Canto II; Excitation 494 nm) Populations from
80,000 – 100,000 cells are considered an adequate sample. Data was then analyzed using
FlowJo software (Tree Star, Inc.). Gates were established to select the cell population.
Additional FlowJo tools allow for mapping cell divisions across scaffold types, enable
determination of the percentage of cells divided, and calculate proliferation index, the
average number of cell divisions a single cell undergoes. Flow cytometry analysis was
repeated on Day 5 (data not shown).
3.3.8 Statistical analysis
Data collected from bi-daily cell counts, as well as proliferation index and percent di-
vided terms derived from flow cytometry data, was analyzed using standard ANOVA
techniques in conjunction with the Tukey test for multiple means comparison. Statis-
tical analysis was performed using OriginPro 9 Software.
3.4 Results
3.4.1 Characterization of rigidity and protein adhesion on elec-
trospun mesh
Fibrous electrospun mesh provides us with a platform the desired high surface-to-volume
ratio and flexibility in the end form. It is durable, easy to handle, and mimics the
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structure of an extracellular matrix. Mesh was spun from different compositions of
PDMS and PCL blends, but it is imperative for us to determine if this rigidity response
is preserved as PDMS mesh is cured in air. AFM techniques have been applied to
the topographic imaging and mechanical measurement of electrospun fibers [Cronin-
Golomb and Sahin, 2013,Nandakumar et al., 2013].
To this end, using a 4.5 µm-diameter polystyrene tip on the order of the size of a
T cell, we have gathered rigidity measurements based on what a cell-sized particle may
actually sense, see Figure 3.3. These measurements do not reflect the stiffness of each
solid individual fiber, rather, they reflect the resistance produced by a woven porous
substrate. As we expect the tip to be much stiffer than the substrate, and the thickness
of the mesh is known to be 50 – 100 µm (sufficiently thick to be considered infinite for
indentation measurements), we can assume the substrate is homogeneous and employ
the Hertz method for curve analysis. Again examining stiffness on the size scale of
individual fibers (300 nm - 1 µm), that is to say indenting with a tip smaller than this
size, we would expect AFM measurements to reflect the rigidity of the homogeneous
bulk material. In this case, we conduct indentation with a larger AFM tip because are
interested in what the whole-cell system perceives.
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Figure 3.3: Schematic of AFM probe 4.5 µm in diameter interacting with electrospun
mesh for size comparison.
AFM indentation measurements were conducted over a wide range of PCL-PDMS
blends, as shown in Figure 3.3. PDMS mixed 10:1 with its crosslinker blended with
PCL produced mesh of more varied and often stiffer regions. Interestingly, though PCL
is known to exhibit the most rigid bulk properties, in this format the local rigidity is
less stiff than in the PDMS-PCL blends. Furthermore, in cases where PDMS is mixed
at a ratio of 50:1 with its crosslinker, softer rigidities were achieved when blended with
a greater ratio of PCL (1:1 as opposed to 4:1). It may be thereby speculated that
PCL incorporated into the mesh solution lowers the local rigidity. This may be due to
an improved ease of spinning and a more stable curing of fibers resulting in increased
porosity or increased mesh resilience. The proportion of PCL in solution does not
appear to correlate with pore size but it may be worthwhile to examine porosity, or the
prevalence of pores (Table 3.1).
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Figure 3.4: AFM indentation measurements across all mesh spun from PDMS-PCL
blends with PCL-only and PDMS sputter controls. Each point represents up to three
indentations at a single region. Standard deviation is shown.
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3.4.2 T cell penetration into and interaction with mesh topol-
ogy
Cells have long been known to sense and respond to mechanical stimuli in their envi-
ronment. The rigidity-based and topographical implications of the PDMS-PCL blend
mesh on cell activation and expansion are characterized here. Mesh of sufficiently large
pore size also encourage cell infiltration and ensure expansion efforts stimulate a greater
number of cells. In order to better visualize cell penetration into the mesh, mesh was
incubated with a fluorescently labeled antibody linker on to which activating antibod-
ies were mounted. Cells stained with carboxyfluorescein succinimidyl ester (CFSE), a
fluorescent dye that is retained stably within the cells for long periods, even through
several divisions, were seeded onto mesh for 12 - 18 hours to ensure sufficient time to
penetrate the mesh. Confocal images show cells penetrating deep into the mesh across
all mesh blends. Cells may also be seen interacting with individual fibers, an advantage
of the increased surface area-to-volume ratio.
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Figure 3.5: Confocal images across mesh blends show cell penetration into mesh and
interaction with fibers.
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3.4.3 T cell stimulation and expansion on electrospun mesh at
short and long time points
To assess the capacity of PDMS-based fibrous scaffolds for T cell expansion, substrates
were prepared accordingly. Mesh were first treated with protein linkers, either goat-
anti-mouse IgG or Protein A, to improve orientation and binding of antibodies. A 4:1
mixture of activating antibodies CD28.6 and OKT3 was then presented via linkers on
the surface of fibrous mesh structures. In the previous chapter as in rigidity studies
on planar PDMS, successful activation was achieved with nave human CD4+ T cells
[OConnor et al., 2012]. We chose to measure proliferation of a CD4+/CD8+ population,
more representative of the starting population of T cells currently utilized in many
adoptive immunotherapy studies. Cytotoxic CD8+ T cells directly engage pathogens,
while helper CD4+ T cells secrete cytokines and interact with immune cells to hone
and drive the response of the immune system.
The uniformity of initial adhesion of cells across varied substrates directly impacts
quantification of cell activation and expansion at later (Day 3 and Day 15) time points.
In efforts to address this discrepency, we measured initial cell adhesion onto mesh at
2 and 12 hour time points. The number of cells adhered onto mesh varied between 60
- 70% of cells initially seeded, at both time points. Alternative coating protocols and
mesh of higher porosity could be implemented to increase initial cell adhesion.
For expansion studies, cells are stained with CFSE; thereby cell proliferation can be
measured by assessing the halving of conferred fluorescence within daughter cells after
each division. Cells were analyzed for the percentage of cells divided and proliferation
index, the average number of divisions each original cell underwent, on both Day 3 and
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Day 5 after seeding. Cell populations were counted to assess doublings on Day 3 and
every other day thereafter for the lifetime of the population.
As both Protein A and goat-anti-mouse IgG have been shown to adequately bind
antibodies to polymer substrates, we began with an investigation into which linker is
best suited to this platform (Figure 3.6). 10:1/4:1 and 10:1/1:1 polymer mixtures were
spun into mesh and then coated with either Protein A or goat-anti-mouse IgG linkers, to
which activating antibodies attached. ANOVA and Multiple Means Comparison Tukey
testing at the three day time point showed statistically significant higher percentages
of cells divided on 10:1/4:1 mesh treated with IgG over the same mesh treated with
Protein A (p = 0.04114). Additionally a significantly higher percentage of cells divided
with the Dynabead control as compared to both blends of mesh treated with Protein A
(for 10:1/1:1, p = 0.02046; for 10:1/4:1, p = 0.00597; n=3) . No statistically significant
differences were observed in terms of the proliferation index. Two-way ANOVA sta-
tistical methods applied across the maximum number of divisions for each sample and
across flow cytometry data did not yield additional insights into the effect of protein
linkers on cell expansion. Additional studies will need to be completed to optimize
antibody presenation on the mesh platform.
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Figure 3.6: Expansion data from 1:10 PDMS-PCL blends with Protein A or IgG anti-
body linkers (A) Doublings measured at Day 3 and every other day thereafter, standard
error shown; (B) Representative CFSE data at Day 3; (C) Flow cytometry analysis in-
cluding the percentage of cells divided and the proliferation index. Standard error
denoted, n = 3.
Comparing the peak doubling value for each sample across all days, the Dynabead
control and both PDMS-PCL blends treated with goat-anti-mouse IgG showed a statis-
tically significant difference over unstimulated cells. Owing to the superior performance
of goat-anti-mouse IgG over Protein A, this linker was employed in the following studies
described here.
These early studies shaped the next stage of experimental design and mesh itera-
tions. AFM indentation studies described in Figure 3.4 show that PDMS mixed 50:1
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with its crosslinker, blended with PCL, and then spun into mesh produce less rigid
more uniform substrates. This, together with fabrication parameters that allowed for
more diverse iterations of this particular fiber form, led us to produce more varied fibers
mainly from blends containing 50:1 PDMS. The following study explored the activa-
tion and stimulation of CD4+/CD8+ T cells across 50:1 PDMS – PCL polymer blends
(Figure 3.7). Blends were tested in nanometer- and micrometer-diameter fiber formats.
Additionally, both aligned and unaligned formats of meshwere procured. Aligned fibers
may be more easily manipulated by T cell interaction, thus encouraging greater pene-
tration depth.
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Figure 3.7: Expansion data from multiple 50:1/1:1 and 50:1/4:1 with PCL in both
aligned and unaligned forms. (A) Doublings measured at Day 3 and every other day
thereafter with standard error bars; (B) Representative CFSE data at Day 3 ; (C)
Flow cytometry analysis yields the percentage of cells divided and the proliferation
index with standard error, double asterisks denote statistical difference from Dynabead
control p < 0.05, n = 3.
The proliferation index of 50:1/4:1 aligned nanofibers is significantly higher the
Dynabead control (p=0.00929). Additionally the proliferation index of the 50:1/1:1
aligned microfibers is higher than that of the Dynabead control (p= 0.08804). Though
we presume values of proliferation index and percent of cells divided at Day 3 will
predict later expansion success, assessing for peak doubling values across all samples
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we find there is no statistical difference in terms of the percent cells divided across all
stimulated samples. Moreover there is no apparent correlation between alignment of
mesh and expansion success, by any of the three metrics. Two-way ANOVA statistical
analysis conducted across the maximum number of divisions for each sample and across
flow cytometry data also did not yield any additional insight into mesh performance.
Additional studies will need to be completed to optimize this mesh platform.
We also compared T cell stimulation and expansion across 50:1 PDMS blended 1:1
with PCL to form mesh with a range of diameters and aligned and unaligned PCL
controls (Figure 3.8).
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Figure 3.8: Expansion data from 50:1 PDMS-PCL blends with PCL-only mesh controls
in both aligned and unaligned forms. (A) Doublings measured at Day 3 and every other
day thereafter, standard error shown here where n=3; (B) Representative CFSE data at
Day 3; (C) Peak doubling of each sample over expansion period, single asterisk denotes
statistical difference from Dynabead control p < 0.1; (D) Flow cytometry analysis
yields percentage of cells divided and the proliferation index with standard error, double
asterisks denote statistical difference from Dynabead control p < 0.05, n = 3.
The proliferation index measured at Day 3 for 50:1/1:1 aligned micrometer-diameter
mesh is significantly higher than that of Dynabeads® (p = 0.04788). Comparing the
peak doubling value for each sample, 50:1/1:1 unaligned micrometer-diameter mesh
is yields a greater number of doublings overall than the Dynabeads® control (p =
0.0937). Furhter investigation via two-way ANOVA techniques across the maximum
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number of divisions for each sample and across flow cytometry data did not yield
additional insights into mesh performance. Though PCL has the stiffest bulk rigidities
and the softest local rigidities measured via AFM indentation, it does not stimulate
cells as well as unaligned 50:1/1:1 micrometer-diameter mesh. Future experimentation
will establish an optimal mesh design for cell expansion efforts.
3.5 Discussion
The results in this chapter highlight a number of key findings. Firstly, mesh with soft
local rigidities can be produced by electrospinning polymers with rigid bulk properties.
Secondly, in terms of scaffold topology, alignment of fibers does not appear to influence
T cell activation; rather the diameter of spun fibers may impart a greater effect. Lastly,
based on our most recent findings we conclude that 50:1/1:1 spun into micrometer-
diameter mesh is the most effective formulation for inducing T cell activation.
Work in the previous chapter attests to the role of rigidity sensing in T cell acti-
vation. In this chapter we were able to assess the local rigidity across a number of
blends for the PDMS-PCL scaffold expansion platform. Despite being characterized by
relatively stiff bulk properties, polymers spun in pure and blended forms exhibit much
softer rigidities in mesh form. This may be explained in part by the porosity element
of the mesh material and by the give or resiliency of the woven platform.
However there was no trend observed relating the bulk rigidity of the contributing
polymer and its local rigidity in mesh form. PCL spun alone, possessing the most rigid
bulk properties, showed the softest local rigidities; while 1:10 PDMS blended with PCL
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had comparatively less rigid bulk properties but showed the stiffest local rigidities and
greatest variation region-to-region. As there are no appreciable differences in pore size
to explain the differences in rigidity, the porosity of the substrate, the frequency of pores
in a given volume, may account for this discrepancy. To this end porosity of the scaffold
may be measured using mercury porosimetry as a part of future investigations [Lu et al.,
2003].
The proportion of PCL in the polymer blend may also have bearing on the local
rigidity. If we consider 50:1 PDMS blended with PCL, it appears that with an increased
ratio of PCL (4:1 to 1:1 PDMS:PCL), local rigidity is decreased. This may be due to
some contributing stabilization factor imparted by the PCL during the curing process.
Nevertheless local AFM indentation measurements of mesh spun from PCL alone and
50:1 PDMS with PCL blends show sufficiently consistent and adequately soft rigidities
to take advantage of the previously established rigidity response.
Deliberating design and implementation of a scaffold T cell activation platform, the
role of antibody binding and mesh topography in modulating cell response is also im-
portant to consider. O’Connor et al demonstrated that that the amount of antibody
adsorbed on PDMS substrates across a range of rigidities is equal despite changes in the
ratio of base polymer to crosslinking agent. PCL substrate has been shown to appre-
ciably bind proteins, which understandably decreases after BSA blocking; however, the
concentration bound is at least in part dependent upon the particular protein [Oliveira
et al., 2014, Yin et al., 2009]. Further work may be conducted to investigate unifor-
mity of antibody presentation on electrospun mesh, as the concentration of antibody
presented is known to have a significant effect on cell activation. Differentiating the
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cell’s response to antibody presentation from its response to substrate rigidity can aid
in the design and optimization of this platform. This assessment in itself has thusfar
presented technical challenges. Antibodies bound to fibers would be difficult to assess
through traditional fluorescence imaging methods. Mesh are by nature not flat and
the variation in number and direction of fibers could not be adequately captured in
a single plane. The top layer may be sufficiently captured and tiled to ensure proper
characterization, but with the level of penetration that we hope to achieve, the depth
of the mesh is difficult to assess. Confocal microscopy was employed to examine cell
penetration and interaction with mesh fibers, but is not a suitable means for assessing
antibody presentation owing to confounding factors such as sample bleaching.
Topography, especially that on the nano-scale, of electrospun mesh has also been
shown to modulate cell adhesion and differentiation [Yim et al., 2007]. Saino et al.
showed an increase in inflammation associated with planar PLLA film and electrospun
PLLA microfibers over electrospun PLLA nanofibers [Saino et al., 2011]. This study
showed higher levels of cytokine and chemokine secretion by macrophages seeded on
microfibers over nanofibers. Additionally, they do not report any significant difference
in cell activation dependent upon the alignment of the fibers. We also find that the
alignment of fibers does not appear to influence T cell activation. Based on our findings
we show that 50:1 PDMS blended 1:1 with PCL and spun into micrometer-diameter
mesh is the most effective formulation for inducing T cell activation. Comparing the
peak doubling value for each sample, this formulation exhibits a significant advantage
in expansion of T cells over the Dynabeads® control (p < 0.1).
Proliferation index, the average number of divisions a cell in the population under-
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goes, and the percentage of cells in a population that divide are assessed on Day 3 of
culture and meant to predict the success of the expansion. In the second set of ex-
pansions, the proliferation index of the Dynabeads® control is statistically significant
over 50:1 PDMS blended with 4:1 PCL aligned nanofibers (p < 0.05) and does go on to
predict a less successful cell expansion. Additionally the proliferation index measured
at Day 3 for 50:1 PDMS 1:1 PCL aligned micrometer-diameter mesh is significant over
the Dynabeads® control (p < 0.05) and the same expansion goes on to be the most
successful, even surpassing the positive control in the extended expansion (p < 0.1).
Therefore our findings conclude that the alignment of fibers seems to be of little con-
sequence to cell stimulation; however, larger fiber diameters (micrometer-scale) may
induce greater activation than smaller (nanometer-scale) fibers. These results will in-
form future iterations of this mesh platform and enhance adoptive immunotherapy by
providing a new level of control over the ex vivo expansion process.
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Chapter 4
Conclusions and Future Directions
The primary aim of this body of work is to explore the influence of substrate rigidity
on the activation and expansion of human T cells and use this knowledge towards
the development of more specialized, more successful clinical platforms for adoptive
immunotherapy. A polyacrylamide gel system with rigidities spanning 10 kPa to 1 MPa
showed a maximum human CD4+ T cell activation at rigidities between 100 and 200
kPa, with lower activity observed outside of this range. This is consistent with human
CD4+ T cell activation on a PDMS elastomer system as reported by O’Connor et al,
and supports that the rigidity response is substrate-independent [OConnor et al., 2012].
These results are also in line with a biphasic cell stimulation response. Early studies
suggest this could also be true for the murine T cell model, but a more extensive range
of rigidities should be tested to establish a biphasic trend and reconcile results with
studies of human cells [Judokusumo et al., 2012]. In order to further understand the
motor-clutch model’s applicability or adaptability to T cell mechanosensing, traction
forces should be examined. Our group has successfully conducted single-cell live imaging
studies to investigate traction forces on PDMS pillars. If pillar systems could be made
to approximate the ideal local substrate rigidities of the designed gels, we would have
the opportunity to better understand force generaiton at the TCR complex and its
impact on T cell response to rigidity [Bashour et al., 2014]. Moreover, the biphasic
response of both cell stimulation and traction forces would be considered supportive of
a powerful link between immune biology and mechanobiology known in other systems.
Alternatively, the absence of biphasic traction force response could signify that cells
operate entirely in the extremes of the rigidity model, or that a different model may
be more informative. In particular, the stick-slip model suggests a mechanism for
maximizing signaling at intermediate molecular strains, with lower activity observed
outside of this range [Margadant et al., 2011].
The agreement and adaptation of the motor-clutch model notwithstanding, changes
in cytoskeletal structure upon cellular activation signal the role of actomyosin in T cell
mechanosensing. In fact, work in our lab (unpublished data) and others suggest large
whole-cell systems are at work in cytoskeleton remodeling after T cell triggering [Kumari
et al., 2014]. The wider rigidity range of this hydrogel system offers the capability to
examine previously unexplored cell behavior in the upper range of biological tissue
stiffness [Levental et al., 2007]. In particular, it will aid our lab in the investigation
of the actin as an indicator of TCR triggering. The development of a comprehensive
model of T cell mechanosensing would enable a greater understanding of the underlying
pathways driving activation and could be put toward the advancement of adaptive
immunotherapy technologies.
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Work delineating the response of T cells directed by substrate rigidity thus far has
guided the development of a new platform for clinical cell expansion. Electrospun
mesh with highly-tuned rigidities offers high surface area-to-volume ratio for improved
cell activation and expansion. Though the system has not yet been optimized we can
report that the alignment of fibers seems to be of little consequence to cell stimulation;
however, larger fiber diameters (micrometer-scale) may induce greater activation than
smaller (nanometer-scale) fibers. This observation requires additional investigation,
and it likewise may be useful to examine changes in pore size and overall porosity of
the substrate. To better project the success of stimulation future studies may also
employ techniques to track cell size, an early indicator of the level of activation.
Aside from increased doublings, the electrospun mesh platform has the potential to
direct cell differentiation. In results published by our collaborators, softer substrates
where shown to enhance nave CD4+ T cell Th1-like differentiation [OConnor et al.,
2012]. Physiologically, Th1 helper cells support the cellular immune system, maxi-
mizing the potency of macrophages and the proliferation of cytotoxic CD8+ T cells.
They have also been shown to be important for efficacy in preclinical immunotherapy
models [Nishimura et al., 2000]. The Th1-like differentiation of nave CD4+ T cells is
promoted by the production of IFNg in helper T cells. To this end, work will be done
to assess IFNg yield in culture, a measure of intercellular effector cytokine expression
of stimulated CD8+ T cells. Rigidity-dependent preferential proliferation and differen-
tiation of a certain T cell population could be a useful alternative to cytokine-directed
differentiation to meet the needs of clinical applications.
Looking ahead to the potential commercialization of electrospun mesh for T cell
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expansion, we must consider the following. To establish this platform as a superior
expansion modality, the electrospun mesh must perform as well as or better than the
current clinical gold-standard, Dynabeads®. Dynabeads offer a high surface area-
to-volume ratio, as does the electrospun mesh, but does not take advantage of the
T cell’s increased activation on softer surfaces, as we’ve shown here. Limits to the
efficiency of separating Dynabeads from activated cells prior to injection are also known,
making the mesh a potentially safer alternative [Levine et al., 1998]. In future iterations
electrospun mesh can be spun from NuSil, a set of elastomers with master files at the
FDA, mitigating regulatory challenges.
As the target of adoptive immunotherapies shift, from dispatching dendritic cells
migrating to the lymph node to induce T cell activation toward stimulating T cells in a
process free of APCs, a more controlled approach is required. Exploring the underlying
mechanisms of T cell activation and proliferation will lead to the development of more
potent immunotherapies. Rigidity-tuned electrospun mesh, an early example of such,
has met with success, though in its early stages. Future work in this direction will look
to optimize this platform, yielding improved cell expansion results important in the




Medicine in a Changing Healthcare
Landscape
5.1 The Current Healthcare Climate
It is no secret that our healthcare system is in the midst of significant change. With the
success of medical technologies and consequential lengthening of the average lifespan,
the focus of the healthcare landscape is shifting from providing acute patient care to
the treatment and prevention of chronic illnesses [Emanuel, 2014]. As new discoveries
are made and new technologies produced, new levels of coordination and cooperation
must be implemented to unite the work of hospitals, physicians, clinical care workers,
patients, insurers, drug and device manufacturers, and regulatory agencies in adapting
these scientific advancements.
A more rounded approach is being taken to the provision of medical services: offering
a wider range of healthcare services through a number of new outlets. After-hours
clinics and some drug and retail stores, who have primarily dealt in pharmaceuticals
for example, are now building to offer a wide range of primary healthcare services.
These new outlets together with established primary care physicians (PCPs), nurses,
social workers, and hospital networks will provide a new and formidable system of
healthcare providers. The overarching system seeks to serve patients at various wellness
stages: through prevention, diagnosis and treatment of disease, as well as maintenance
of remission state. In the midst of all of this, patients are being encouraged to take
greater involvement in and responsibility for their health and well-being, aside from
solely relying on their PCP [Bielamowicz, 2014]. In time we may see the PCP’s role
shift to better informing the patient, motivating long-term behavior changes, addressing
new needs, and helping to coordinate available care providers so that the patient can
stay invested in their treatment plan and better maintain their lifestyle.
On this level of patient care provision, it is obvious that a great deal of effort will
be required in coordinating the work of an expanding network of healthcare providers.
Comprehensive patient profiles would allow information to be transferred between phar-
macies, clinics, physician’s offices, etc. to offer a centralized source of patient informa-
tion, treatment options, and pharmaceutical records to devise and maintain a consistent
treatment plan.
Family health history forms an important foundation for comprehensive patient
profiles. This history reflects an amalgamation of shared genetic, environmental, and
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lifestyle factors that can be used to gauge a patient’s risk for certain diseases [Chan
and Ginsburg, 2011]. Yet, for a variety of reasons, not everyone has a complete family
health history and even if so, these histories may not provide a whole picture of the
individual’s risks.
Instead evidence-based health risk assessments have been developed to evaluate
a patient’s risk and prioritize clinical approaches to disease events, such as coronary
heart disease and breast cancer; however they are highly underutilized [Kannel et al.,
1961,Gail and Greene, 2000]. This low implementation rate may be due to insufficient
standards for the clinical data required or algorithm employed [Liu et al., 2006]. These
assessments also suffer, notably, from poor integration into most health information
technology systems. However computerized clinical decision support systems have been
developed and are finding greater success in practice, see Figure 5.1 [Osheroff et al.,
2007].
These systems assimilate patient information into user-friendly interfaces to improve
accessibility to patient information and knowledge for healthcare providers. Work is still
underway to expand this technology and incorporate electronic health records which
would provide additional support for diagnostic and treatment decisions [Bennett and
Glasziou, 2003,Shea et al., 1996,Walton et al., 1999].
5.2 The Role of Personalized Medicine
A similar evolution of strategy is occurring in parallel with research and development
drivers of the healthcare landscape. With the progress of biomedical research, no-
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Figure 5.1: Integration of molecular, clinical, and genetic factors can be assessed by
personalized diagnostics and impact therapeutic options [Bottinger, 2007].
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tably successful mapping of the human genome in 2003, scientists have come to better
understand the causation, contributing factors, and manifestations of many diseases.
This insight is very valuable in that treatments can be preemptively designed based
on genetic evidence, which can be obtained from a patient via a simple cheek swab.
This technology may even one day see integration into clinical decision support sys-
tems; however, there are still challenges in implementation as such large data sets and
complex analysis mandate trained users and substantial computing power. Personalized
medicine is the evidenced-based tailoring of medical treatment to a particular patient at
a particular disease state [Fackler and McGuire, 2009,Chan and Ginsburg, 2011]. This
medical treatment is not confined to pharmaceutical or genomic therapies; rather it can
be expanded broadly to encompass one or a culmination of the following technologies
that provide patients with targeted services: genetic testing, biomedical imaging for im-
proved monitoring or design of treatment, prosthetics, and tissue regeneration [Fackler
and McGuire, 2009]. Generally two medical products, a diagnostic device and thera-
peutic product, are developed for cooperative use, though not always through the same
company [Fackler and McGuire, 2009]. Regardless of form, personalized medicine aims
to treat the underlying cause of a disease rather than to simply appease the symptoms.
This realization and subsequent integration of this new form of medicine demands that
healthcare decisions be made based on a combination of a patient’s unique clinical,
genetic, genomic, and environmental data [Chan and Ginsburg, 2011].
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5.2.1 Reserach and Development
Ultimately the field of personalized medicine seeks to provide an optimal treatment
for an individual at any stage of disease progression. As mentioned previously, the
healthcare system is shifting toward aiding patients through prevention of disease and
monitoring of their health, and away from its focus on acute medical treatments. Per-
sonalized medicine has the potential to play a significant role in this transition. It has
the capacity to streamline clinical decision making, lower treatment time, and severity
of illness by pairing patients with effective treatments and avoiding ineffective ones that
may come with harmful side effects. Today drugs are ineffective in 38 - 75% of patients
who suffer from major illnesses including depression, diabetes, and Alzheimer’s. The
failure of these treatments may be due to a wide range of factors: complex interactions
at the interface of the drug and target, subjection of the drug other chemical pro-
cesses in the body, inappropriate dosages, and even noncompliance. With personalized
medicine, many of these considerations can be identified outright and decisions can be
made in advance. Effective therapies may be prescribed more quickly and accurately,
based on genomic evidence, rather than through trial-and-error.
Genotypes are often studied to understand what underlies certain disease pheno-
types. Interestingly, there are some cases where patients demonstrate the same disease
phenotype but distinct genetic profiles. In these instances the same treatment plan may
work differently or fail when applied to both types of patients. Therefore drug interac-
tion, chemical messengers, and metabolism processes in the body must be considered,
which may lead to the development of new more personalized treatment options [Vo-
genberg et al., 2010a, Janetos, 2009]. Some of the most notable benefits of what has
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been termed pharmacodiagnostics or thereonostics, the use of molecular analysis to op-
timize disease management, include better medication selection, safer dosing options,
and improved drug development in clinical trials.
The work in this thesis primarily seeks to modulate an adoptive immunotherapy
for the treatment of chronic lymphoid leukemia and has been adapted to acute lym-
phobastic leukemia as well. This adoptive immunotherapy technique is founded in the
genetic manipulation of a patient’s own T cells. Over the span of approximately 10
days, cells are subjected to chimeric antigen receptor (CAR) engineering. This cellular
engineering adds a receptor to the cell’s surface to target leukemia cells, and once the
antigen is found the leukemic cell presenting it is destroyed. The genetic modification
process also inserts a viral vector mechanism into the T cell which triggers lymphocyte
expansion and proliferation upon encountering a leukemic cell to seek out and destroy
the rest of the cancerous population. Early forms of this treatment have been successful
in treating a small subset of the adult patients with CLL and of the adult and children
with ALL that failed to respond to other available treatment options [Chustecka, 2013].
This type of personalized medicine is being applied to different subpopulations of can-
cers and its use and development may be improved by additional screening practices,
which can only be established as implementation increases.
Though the impact of genomic sequencing is widely cited as the preeminent driver
of personalized medicine, a number of medical devices can be modified on an indi-
vidualized basis to improve performance. Anatomy, physiology, and environment are
all important variables to consider; moreover, we currently possess the technological
capacity to directly quantify and utilize such characteristics for personalized device de-
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velopment. Examples of personalized medical devices in various stages of development
and manufacturing include a 3D printed tracheal splint, a tinnitus masker auditory aid,
and an artificial pancreas device system [Fackler and McGuire, 2009,Zopf et al., 2013].
Similarly, this dissertation takes early steps in utilizing substrate rigidity in the design
of an expansion platform that could one day be used to better expand and differentiate
T cell populations to fight a particular form or stage of cancer.
5.2.2 The FDA’s Regulatory Strategies
Even in its early stages, personalized medicine has given way to more informed ways
to predict risk, screen for carriers, and direct clinical diagnosis, prognosis, and manage-
ment of disease based on genetic variation [Collins, 1999]. As a result of such promise,
the FDA has worked extensively to evolve in response to and in anticipation of sci-
entific progress [Fackler and McGuire, 2009]. First and foremost, the FDA focuses on
ensuring the safety, efficacy, and security of healthcare products. Not only do they eval-
uate the benefits and risks of scientific evidence in deciding whether to approve new
products but also strictly regulate manufacturing practices. However nearly 100,000
deaths annually in the US may be attributed to adverse treatments effects. The FDA
recognizes personalized medicine for its prospective role in reducing this number of ca-
sualties. Additionally, it sees the potential in a more solid understanding of patient
response variability to speed the development of drugs and approval to market [Fackler
and McGuire, 2009].
To better support the advancement of the field of personalized medicine, the FDA
has taken strides to facilitate the research and development surrounding new technolo-
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Figure 5.2: Probablility of drug success to market by stage of develpment [Arrowsmith,
2012].
90
gies and providing assistance to streamline regulatory processes. In recent years, fewer
and fewer drugs have endured the many phases of clinical trials to successfully enter the
market, see Figure 5.2. Currently drugs and devices face a host of regulatory challenges
which can only become more complex in the onslaught of newly developed genetically
guided therapies. Given its relative infancy in the market and propensity for fast and
continuous evolution, emerging biomarkers will be challenging for the FDA to validate
both clinically and analytically. Furthermore, as diagnostic and therapeutic products
are often co-developed and not necessarily by the same company, regulatory agencies
must have the wherewithal to collaborate amongst each other and between produc-
tion companies to coordinate product validation, reviews, and oversight [Fackler and
McGuire, 2009].
The FDA has commissioned several regulatory agencies in efforts to evolve and guide
policy decisions in the changing healthcare landscape. With the sequencing of the hu-
man genome, the Center for Biologics Evaluation and Research (CBER), alongside the
FDA’s other medical product centers began the arduous task of creating and implement-
ing regulatory processes, policies, and infrastructure to meet the complex challenges of
this booming field. CBER in particular has integrated new genetic technologies into
regulatory oversight to speed the development and availability of complex biological
products, including the introduction of manipulated cells into the body to fight disease.
It has developed a consortium of intramural research scientists who work with other
researchers within a variety government agencies to ensure these new therapies are safe
and effective [Fackler and McGuire, 2009].
Also of note, in 2002 the Center for Drug Evaluation and Research together with the
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Drug Industry Association engaged pharmaceutical and biotechnology industry part-
ners to discuss scientific development and regulatory policies surrounding pharmacoge-
netics. From these workshops the Voluntary Exploratory Data Submission Program was
formed as an opportunity for drug and device companies to discuss genetic information
with the FDA outside of a formal review process. The Office of In Vitro Diagnostics
and Radiological Health likewise stemmed from this collaboration, founding a central-
ized unit for the comprehensive regulation for all diagnostic device activity [Fackler
and McGuire, 2009]. From this point, it is imperative that standards be establsihed to
ensure testing reliance and uniformity [Vogenberg et al., 2010b].
These examples are part of a larger effort by the FDA that have served to encourage
an exchange of information between sponsors and regulatory agencies for the research
and development of personalized medical treatments.
5.2.3 Economic and Ethical Considerations
In order for personal medicine to gain traction with market entry its many shareholders,
including but not limited to patients, clinicians, drug and device manufacturers, IT
specialists, healthcare providers, insurers, educators and regulators, must feel secure
in their adaptation of new technologies and the invest the creation of a supportive
infrastructure [Fackler and McGuire, 2009].
Economically it stands to reason that by preemptively selecting drugs and dosages
based on genetic and metabolic testing rather than assuming the financial and health
risks of traditional trail-and-error prescribing, overall healthcare costs can be reduced.
With escalating costs, healthcare payments are progressively being assumed by patients
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themselves which lends them a greater voice in regulatory and policy decisions [Vogen-
berg et al., 2010b]. It is paramount that affordable and effective healthcare be offered;
however, for biotechnology and pharmaceutical companies this decrease in drug sales
translates to a decline in profits. With the current one-size-fits-all model for pharma-
ceutical sales, blockbuster drugs occupy huge market shares even though they are not
always effective and may cause harmful side effects. With the advent of personalized
medicine, companies will need to adapt their business models to foster combination
diagnostic-therapeutic products and comply with regulatory submissions. Biopharma-
ceutical companies can also adjust their product portfolios and market approach to
improve profitability through other avenues. In some instances, the government offers
them incentives to develop drugs to treat smaller disease populations, especially where
alternative therapies do not exist. Additionally, industry players have the opportu-
nity to improve the rate of use of drugs currently limited by poor efficacy or safety
issues, through aiding prescribers in identifying patient populations who could stand
to benefit [Vogenberg et al., 2010b,Mancinelli et al., 2000].
Scientific advancements may only minimally impact the total cost of patient care,
still antiquated reimbursement practices and legislation may create barriers to suc-
cess [Vogenberg et al., 2010c]. Insurers consider many factors when formulating cover-
age policies for personalized medicine; however, many will likely to continue to resist
supporting such claims until clinical evidence for efficacy strengthens [Hresko and Haga,
2012]. In the face of expensive diagnostic and therapeutic products, the return on in-
vestment of disease prevention has not been shown to offset the initial costs [Vogenberg
et al., 2010b]. Payers will need to take the time to experiment with their approach to
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personalized medicine, gathering data to aid them in calculating the cost benefits of the
services for their organization. This may include creating network and negotiating test-
ing costs with laboratories to secure testing costs that can then result in savings passed
along to customers. Ultimately insurers will be faced with deciding which medical
expenses to cover in their policies which will depend on a diagnostic or therapeutic’s
clinical utility and potential to impact physician decision-making [Vogenberg et al.,
2010c]. Otherwise patient demand for personalized will most probably continue to be
mitigated by their ability to pay. The introduction of new therapeutics and diagnostics,
especially those that involve genetic information, requires the establishment of policies
to protect patients, physicians, and other healthcare workers. The Health Insurance
Portability and Accountability Act of 1996 (HIPPA) was put in place to protect the
privacy of patient information as it is stored, accessed, or processed. Genetic informa-
tion must be held under particularly stringent regulations as it can reveal facts not only
about the individual but also about certain blood relatives [Vogenberg et al., 2010b].
The Genetic Information Nondiscrimination Act of 2015 further protects the privacy
of genetic information from use as a foundation for health insurance underwriting deci-
sions and as a basis for career decisions at the hands of an employer [of Human Genet-
ics, 2007,Research!America, 2010]. The goal of these regulations is help patients to be
more secure in accessing genetic testing and pave the way for personalized medicine [Vo-
genberg et al., 2010b]. As the Department of Health and Human Services Secretary
Kathleen Sebelius announced the HIPPA privacy rules she stated “. . . consumer confi-
dence in genetic testing can now grow and help researchers get a better handle on the
genetic basis of diseases. Genetic testing will encourage the early diagnosis and treat-
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ment of certain diseases while allowing scientists to develop new medicines, treatments,
and therapies” [Zeidner, 2009]. Moreover, these policies together with new regulations
passed under the Affordable Care Act ensure insurace coverage for people with genetic
predispositions for disease as well as pre-existing medical conditions. In order to im-
plement personalized medicine in the clinical space, physicians must be convinced of
its accuracy and efficacy bringing no harm whatsoever to the patient. At this time
physicians are not poised to support practices of personalized medicine. This is in part
because organizations that support clinical standards have not yet offered their support
of diagnostic and therapeutic strategies. At the same time as patient advocates they
recognize that the implementation of personalized medicine may also present ethical
dilemmas. For instance, individuals must never be coerced into participating in genetic
testing owing to the amount of information it may reveal regarding other risks. Though
policies have been put in place to protect a patient’s privacy, it is still possible for an
insurer or a state government to require genetic testing to determine drug safety or
efficacy in order to sidestep unnecessary cost burdens [Vogenberg et al., 2010b]. Nev-
ertheless Patients stand to reap huge benefits and they themselves could be a driving
proponent force of this new field of medicine. Knowing more about potential health
risk and genetic predispositions could motivate people to maintain a healthy lifestyle
and address health concerns early on. However advocacy groups have not yet been
established and access to such treatments are not yet being demanded.
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5.3 Patients and Advocates Guide Medical Research
Efforts
Advocacy groups are taking a larger role in funding, organizing, and soliciting devel-
opment efforts for better treatment options. In the 1980s, AIDS treatment activists
participated as credible players alongside scientists and government officials, changing
the way data is validated and utilized in biomedical research [Epstein, 1995].
More recently, the drug Kalydeco which helps to restore function to a protein made
by a mutated gene has successfully entered the market as a treatment for cystic fibrosis.
Kalydeco was born out of a decade-long collaboration between the Cystic Fibrosis
Foundation (CFF) and Vertex Pharmaceuticals. The CFF ultimately piloted the path
to drug development by undertaking sizable financial and organizational responsibilities.
They took a leading role by advocating for their cause, building the network necessary
to investigate genetic markers characteristics of the disease, organizing participants
to take part in clinical trials, as well as funding research and drug screening efforts.
Additionally, the FDA granted the drug application “priority review” expediting the
review process for drugs that offer major advancements in treatment or therapies where
no alternatives exist [Fackler and McGuire, 2009]. This is a valuable example of the
success that can be achieved when scientists, advocacy groups, and regulatory agencies
work together.
Breast cancer advocates are seeking a similar response. The Artemis Project spon-
sored by the National Breast Cancer Coalition has been recently featured in the news
for its goal to end breast cancer by 2020 through innovative and strategic collabora-
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tion by bringing together various stakeholders. As a preliminary target, the coalition
is sponsoring development of vaccine over the next five years to prevent breast can-
cer [Harris, 2014]. It is no longer just a matter of coming up with funding for scientific
research: patients and their advocates are going to greater lengths to set the focus of
research and bring together experts to answer the questions they deem most important.
With healthcare costs rising and traditional funding sources dwindling researchers will
need to rethink their research strategies. Additionally, if successful, these early collab-
orations will help to shape the way science is conducted in the future. The work of
scientists will become less introspective and self-contained. It will be essential for sci-
entists to reorganize and collaborate more broadly with the government and the public
to address important medical issues.
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. Electrospun mesh is fabricated from a PDMS/poly(caprolactone) (PCL) solution,
courtesy of Dr. Helen Lu at Columbia University. Early on, it was determined that
PDMS could not be spun alone, owing to its low molecular weight. We have ex-
perimented with polymer solutions of different polymer-to-crosslinker compositions of
PDMS and varying ratios of PDMS to PCL, a biodegradable material that serves to in-
crease the molecular weight of the solution. Polymer solutions were blended from both
1:10 PDMS (bulk rigidity ˜ 2 MPa) and 1:50 PDMS (bulk rigidity >100 kPa) (polymer
to crosslinker ratio) either in 4:1 or 1:1 ratios with PCL and spun into mesh. These
polymers are combined in a solvent phase together with a 3:1 ratio of dichloromethane
(DCM) and N,N-dimethlyformadahide (DMF), to achieve a final polymer concentra-
tion of 19% w/v in solvent for the production of fibers with nanometer-scale diameters.
Alternatively a final polymer concentration of 35% w/v in solvent is required for the
production of fibers with micrometer-scale diameters.
In either case, as the fibers are spun, the solvent evaporates. Fibers are extruded
through a spinneret, charged by a high voltage power supply in a range of 10-12 kV,
spaced approximately 10 cm from the grounded collector, covered in foil for easy re-
moval.. For unaligned fibers, the collector plate is fixed while for aligned fibers the
rotating mandrel turns at a rate of 2100 rpm.
In efforts to address a wider range of rigidities, PCL-only mesh was spun at a
concentration of 19% w/v in solvent. For aligned PCL fibers, the rotating mandrel
turns at a rate of 2400 rpm. Alternatively PDMS alone cannot be spun, but was
sputtered through an electrospinning apparatus.
Importantly, processing parameters may be manipulated to generate particular geo-
metrical and structural properties within the scaffold. For instance, fiber diameter may
be decreased by increasing the applied voltage or decreasing the flow rate [Demir et al.,
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2002, Zeng et al., 2003, Sill and von Recum, 2008]. Additionally, there is an optimal
distance for uniform fiber production: overly long or short distances between extraction
and collection components may produce undesirable beading [Zhang et al., 2005,Zhao
et al., 2005]. Composition of the polymer solution also plays a large role in determining
fiber morphology. Wider fiber diameters can be achieved by increasing the viscosity
of a solution, increasing the polymer concentration of a solution, or decreasing con-
ductivity [Zeng et al., 2003, Zhang et al., 2005, Zhao et al., 2005]. Selecting a polymer
with a high molecular weight will reduce beading and improve fiber uniformity [Demir
et al., 2002,Gupta et al., 2005]. By fine-tuning these parameters, electrospun fibers can
be produced with diameters ranging from 2 nm to several micrometers and pore sizes
ranging from a few nanometers to nearly a micrometer [Ahn et al., 2006, Hunley and
Long, 2008,Reneker and Yarin, 2008].
A.2 Mesh characterization
The basic material properties of each mesh is characterized via scanning electron mi-
croscopy, Fourier transform infrared spectroscopy, and tension testing by the laboratory
of Dr. Helen Lu at Columbia University. Scanning electron microscopy (SEM) is an
imaging technology based in scanning a surface with a beam of electrons to determine
topography, capable of resolution better than a single nanometer. In preparation, 5 - 7
nm of gold is sputtered on the fibrous substrate for clearer imaging at higher magnifi-
cations. Fourier transform infrared (FTIR) spectroscopy measures the absorbance of a
sample at each wavelength to determine the presence of certain functional groups in a
molecule.
Samples were tested to failure under uniaxial tension. Specifically, scaffolds cut
from spun sheets (6 cm x 1 cm, n = 5 / group) were secured using custom clamps and
mounted on an Instron mechanical testing device with an average gauge length of 3
cm. Samples were evaluated at a strain rate of 5 mm/min and elongation and elastic
modulus were calculated from the stress-strain curve.
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